[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 315
1. Aliaev IuG, Apolikhin OI, Mazo EB, Vinarov AZ, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations]. Urologiia; 2009 Jul-Aug;(4):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations].
  • The article presents 2-year pilot results of a multicenter, randomized, controlled trial of prostamol-UNO effects on symptoms progression, quality of life, tolerance and safety in patients with early prostatic adenoma.
  • Measurements were also made of changes in Qmax, urine volume, residual urine, size of the prostate.
  • [MeSH-major] Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824382.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno
  •  go-up   go-down


2. Glading AJ, Ginsberg MH: Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. Dis Model Mech; 2010 Jan-Feb;3(1-2):73-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, KRIT1 regulates beta-catenin signaling, and Krit1(+/-) mice are more susceptible to beta-catenin-driven intestinal adenomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thromb Haemost. 2007 Jul;5 Suppl 1:32-40 [17635706.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):247-54 [17954608.001]
  • [Cites] Neurogenetics. 2007 Nov;8(4):249-56 [17657516.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1296-303 [18171987.001]
  • [Cites] Carcinogenesis. 2008 Mar;29(3):666-72 [18204079.001]
  • [Cites] J Cell Sci. 2008 Jul 1;121(Pt 13):2224-34 [18565826.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):923-34 [18604199.001]
  • [Cites] Cardiovasc Res. 2008 Sep 1;79(4):679-88 [18490349.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2770-9 [18641366.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):6920-9 [19029934.001]
  • [Cites] Dis Model Mech. 2008 Nov-Dec;1(4-5):275-81 [19093037.001]
  • [Cites] Nat Med. 2009 Feb;15(2):169-76 [19151727.001]
  • [Cites] Nat Med. 2009 Feb;15(2):177-84 [19151728.001]
  • [Cites] Hum Mol Genet. 2009 Mar 1;18(5):919-30 [19088123.001]
  • [Cites] Dis Model Mech. 2009 Mar-Apr;2(3-4):168-77 [19259391.001]
  • [Cites] Hum Mutat. 2009 Jun;30(6):1003-11 [19370760.001]
  • [Cites] Hum Mol Genet. 1999 Nov;8(12):2325-33 [10545614.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7219-25 [10602475.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1179-91; discussion 1191-2 [10807251.001]
  • [Cites] Asian J Androl. 2000 Sep;2(3):167-71 [11225974.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1049-60 [11381089.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):188-92 [11459890.001]
  • [Cites] Biochemistry (Mosc). 2001 Oct;66(10):1174-86 [11736639.001]
  • [Cites] Acta Haematol. 2001;106(4):148-56 [11815711.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21657-65 [11940574.001]
  • [Cites] Mech Dev. 2002 Sep;117(1-2):363-7 [12204286.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6367-70 [12438216.001]
  • [Cites] Haematologica. 2003 Apr;88(4):429-37 [12681970.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8085-9 [14678957.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52587-97 [14506247.001]
  • [Cites] Development. 2004 Mar;131(6):1437-48 [14993192.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):261-70 [15071551.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):365-76 [15163311.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35127-32 [15166221.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L816-23 [15220112.001]
  • [Cites] Cell. 1989 Jan 13;56(1):77-84 [2642744.001]
  • [Cites] Oncogene. 1992 Sep;7(9):1705-11 [1323817.001]
  • [Cites] Prostate. 1994 Oct;25(4):177-88 [8084835.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • [Cites] J Cell Biochem. 1996 Jun 15;61(4):514-23 [8806074.001]
  • [Cites] Nature. 1996 Oct 17;383(6601):627-30 [8857539.001]
  • [Cites] Mol Carcinog. 1996 Oct;17(2):84-91 [8890957.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2036-41 [9058725.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):93-8 [9066635.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):583-8 [9092940.001]
  • [Cites] Oncogene. 1997 Aug 28;15(9):1043-9 [9285558.001]
  • [Cites] Pancreas. 1998 May;16(4):491-8 [9598810.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Cell. 1999 Jul 23;98(2):147-57 [10428027.001]
  • [Cites] Eur J Cell Biol. 1999 Aug;78(8):561-6 [10494862.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):189-93 [10508515.001]
  • [Cites] Semin Cell Dev Biol. 2004 Dec;15(6):657-63 [15561585.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1950-5 [15374886.001]
  • [Cites] Circ Res. 2005 Feb 18;96(3):308-18 [15662032.001]
  • [Cites] Hum Mol Genet. 2005 Sep 1;14(17):2521-31 [16037064.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 Sep;5(5):391-6 [16131422.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31906-12 [16027153.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cell Cycle. 2005 Nov;4(11):1522-39 [16258275.001]
  • [Cites] Exp Cell Res. 2006 Feb 15;312(4):457-67 [16368435.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5288-99 [16361708.001]
  • [Cites] Cell. 2006 Mar 10;124(5):1055-68 [16530050.001]
  • [Cites] Development. 2006 Aug;133(16):3139-46 [16873582.001]
  • [Cites] J Med Genet. 2006 Sep;43(9):716-21 [16571644.001]
  • [Cites] Dev Dyn. 2006 Nov;235(11):3110-20 [17013885.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1223-34 [17060906.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1658-64 [17106247.001]
  • (PMID = 20007487.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL31950; United States / NIAMS NIH HHS / AR / R01 AR027214; United States / NIAMS NIH HHS / AR / AR27214; United States / NHLBI NIH HHS / HL / P01 HL031950; United States / NIAMS NIH HHS / AR / R37 AR027214; United States / NHLBI NIH HHS / HL / P01 HL078784; United States / NHLBI NIH HHS / HL / HL078784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Krit1 protein, mouse; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins; 0 / beta Catenin; EC 3.6.5.2 / rap1 GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2806902
  •  go-up   go-down


3. Bogdanov AB, Luk'ianov IV, Veliev EI: [Using doxasosine and finasteride combination in the treatment of prostate adenoma]. Urologiia; 2006 Sep-Oct;(5):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
  • The study was made in 2005-2006 of efficacy and safety of combined use of doxasosine and finasteride in patients (n = 50, age 53-83) with symptoms of lower urinary tract dysfunction (LUTD) caused by prostatic adenoma.
  • LUTD severity by IPSS, size of the prostate, maximal and mean urinary flow velocity, functional capacity of the urinary bladder, residual urine, blood pressure, a PSA level, sexual function, were assessed at baseline and after the treatment.
  • The size of the prostate diminished from 55.8 to 46 cm(3) (p < 0.01).
  • Thus, the proposed scheme of combined treatment improves quality of life, voiding; lowers residual urine; is well tolerated; can be recommended as a basic scheme of treatment in patients with a risk of prostatic adenoma progression.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Doxazosin / therapeutic use. Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Prostatic Hyperplasia / drug therapy. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444154.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


Advertisement
4. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Reding DJ, Hayes RB, Church T, Yurgalevich S, Doria-Rose VP, Hickey T, Riley T, Berg CD: Utilization of surveillance colonoscopy in community practice. Gastroenterology; 2010 Jan;138(1):73-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The recommended timing of surveillance colonoscopy for individuals with adenomatous polyps is based on adenoma histology, size, and number.
  • METHODS: We retrospectively queried participants in the Prostate, Lung, Colorectal, and Ovarian Cancer screening trial in 9 US communities about use of surveillance colonoscopy.
  • Subjects whose initial colonoscopy showed advanced adenoma (AA), nonadvanced adenoma (NAA), or no adenoma (NA) findings were included.
  • [MeSH-major] Adenoma / epidemiology. Adenomatous Polyps / epidemiology. Colonic Neoplasms / epidemiology. Colonoscopy / utilization. Community Health Services / statistics & numerical data. Gastroenterology / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):96-104 [12118964.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):129-31 [12118971.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1237-46 [12818263.001]
  • [Cites] Ann Intern Med. 2004 Aug 17;141(4):264-71 [15313742.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 1;20(5):507-15 [15339322.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):989-97 [15998952.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1151-62 [16230069.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] JAMA. 2006 May 24;295(20):2366-73 [16720822.001]
  • [Cites] Ann Intern Med. 2006 Nov 7;145(9):654-9 [17088578.001]
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):874-81 [17244633.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):419-26 [18347350.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jan;7(1):86-92 [18829395.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 May;7(5):562-7; quiz 497 [19138760.001]
  • [Cites] Can Fam Physician. 2001 Sep;47:1811-3, 1815 [11570307.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):619-24 [10702214.001]
  • [CommentIn] Gastroenterology. 2010 Jan;138(1):27-30 [19932659.001]
  • (PMID = 19818779.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000056-440770; United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS151861; NLM/ PMC2813330
  •  go-up   go-down


5. Li FY, Ren XB, Xu EP, Huang Q, Sheng HQ, Lv BJ, Lai MD: RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor. J Zhejiang Univ Sci B; 2010 Apr;11(4):258-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating gene IV (RegIV), a member of the regenerating gene family discovered in 2001, has been found to be involved in malignancy in several different organs including the stomach, colorectum, pancreas and prostate, but the overall expression profile of RegIV has not been reported.
  • To learn more about RegIV, we evaluated its distribution by immunohistochemistry (IHC) in a total of 360 samples including 24 types of normal tissue, 40 benign and malignant lesions, and 18 neuroendocrine tumors.
  • Studies on additional sets of colorectal tumor samples showed that RegIV expression was predominant in colorectal adenoma (87.5%) and peritumoral tissue (100%) but not in cancer tissue (30.8%).

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Feb;13(2):140-6 [10697270.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):59-69 [19740514.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 16;1518(3):287-93 [11311942.001]
  • [Cites] Diabetes. 2002 Feb;51(2):339-46 [11812740.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):185-93 [12455032.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):11-20 [12819006.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):69-76 [14550954.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):963-9 [14559978.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2635-41 [14669303.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1130-6 [15022278.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] J Am Coll Surg. 1994 Aug;179(2):231-48 [8044398.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2237-43 [15788672.001]
  • [Cites] J Pathol. 2005 Oct;207(2):185-98 [16086444.001]
  • [Cites] Gut. 2005 Oct;54(10):1437-44 [15914572.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):137-49 [16401477.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1191-7 [16918991.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1714-20 [17106246.001]
  • [Cites] Lab Invest. 2007 Mar;87(3):304-14 [17260007.001]
  • [Cites] Oncology. 2007;72(5-6):371-80 [18187959.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [ErratumIn] J Zhejiang Univ Sci B. 2010 May;11(5):390
  • (PMID = 20349522.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / REG4 protein, human
  • [Other-IDs] NLM/ PMC2852542
  •  go-up   go-down


6. Alivizatos G, Skolarikos A, Chalikopoulos D, Papachristou C, Sopilidis O, Dellis A, Kastriotis I, Deliveliotis C: Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):427-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • OBJECTIVES: To compare the effectiveness and the safety of photoselective vaporization of the prostate (PVP) to open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: A total of 125 patients with prostate glands >80ml were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, and 12 mo postoperatively.
  • International Prostate Symptom Score (IPSS) and peak urinary flow rate (Q(max)) were chosen as primary treatment-related end points.
  • At 3 mo prostate volume was significantly lower in the OP group compared to the PVP group (median value 10ml vs. 50ml; p<0.001) and remained as such throughout follow-up, whereas prostate-specific antigen values reached statistical difference at 6 mo (median value 2ng/ml vs. 2.4ng/ml; p=0.028).
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Aug;54(2):435-6 [18069122.001]
  • [CommentIn] Eur Urol. 2008 Aug;54(2):436-7 [18069121.001]
  • (PMID = 18069117.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Lopatkin NA, Petrov SB, Sivkov AV, Markov AV, Oshchepkov NN, Bolokhanov IuN: [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial]. Urologiia; 2006 May-Jun;(3):3-6, 8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial].
  • Tamsulone-FS--a novel Russian alpha1A/D-adrenoblocker (Farm-Syntez)--was studied in a randomized multicenter comparative trial in patients with prostatic adenoma.
  • Pilot results agreed with other trials published in the literature and demonstrated tamsulone-FS efficacy and safety for management of lower urinary tract symptoms caused by prostatic adenoma.
  • This drug can be recommended for wide clinical practice in prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889080.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


8. Chepurov AK, Bulantsev DIu: [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urethra / pathology. Urethra / physiopathology. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472005.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 71
  •  go-up   go-down


9. Shen J, Liu J, Xie Y, Diwan BA, Waalkes MP: Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure. Toxicol Sci; 2007 Feb;95(2):313-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung adenoma and adenocarcinoma from adult female mice exposed to arsenic in utero showed widespread, intense nuclear ER-alpha expression.
  • ER-alpha activation was specifically associated with arsenic-induced lung adenocarcinoma and adenoma but not with nitrosamine-induced lung tumors.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Feb;190(2):133-42 [10657010.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1243-55 [14617798.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Curr Oncol Rep. 2004 Jul;6(4):259-67 [15161576.001]
  • [Cites] Clin Lung Cancer. 2004 May;5(6):353-9 [15217534.001]
  • [Cites] Growth Horm IGF Res. 2004 Aug;14(4):261-9 [15231294.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):366-76 [15276416.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):394-404 [15276419.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 7;326(1):218-27 [15567174.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Jan;32(1):65-71 [15514114.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):316-9 [15627066.001]
  • [Cites] J Soc Gynecol Investig. 2005 Jan;12(1):58-64 [15629674.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1459-70 [15735034.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3796-805 [15867376.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3212-8 [15886308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98 [16039940.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11287-91 [16357134.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Toxicol Sci. 2006 Jun;91(2):372-81 [16543296.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Annu Rev Med. 2003;54:73-87 [12471176.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Dec;2(6):709-35 [12503217.001]
  • [Cites] Biochem Cell Biol. 2002;80(3):335-41 [12123286.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):236-44 [12111698.001]
  • [Cites] Lung Cancer. 2002 May;36(2):125-32 [11955646.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):46-53 [11940206.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40 [11911952.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • (PMID = 17077188.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / NIH0011069698; United States / Intramural NIH HHS / / ; United States / PHS HHS / / NIH0011069698; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Carcinogens, Environmental; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite
  • [Other-IDs] NLM/ NIHMS33564; NLM/ PMC2692318
  •  go-up   go-down


10. Berndt SI, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock SJ, Weissfeld JL, Schoen RE, Hayes RB: Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis; 2007 Sep;28(9):1965-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma.
  • To investigate the association between genetic variants in TGFB1 and the risk of colorectal adenoma, we conducted a case-control study of 754 advanced adenoma cases and 769 controls from the baseline screening exam of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • Cases included participants diagnosed with advanced left-sided adenoma (>or=1 cm, high-grade dysplasia or villous characteristics), and controls were subjects without evidence of a left-sided polyp by sigmoidoscopy.
  • Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for the association between each polymorphism and adenoma.
  • The high TGFB1 producer genotypes, -509TT and 10Pro/Pro, were associated with an increased risk of colorectal adenoma compared with other genotypes (OR = 1.51, 95% CI: 1.04-2.20 and OR = 1.37, 95% CI: 1.02-1.86, respectively).
  • These increased risks, particularly for -509TT, were greater for persons with multiple adenomas (OR = 1.89, 95% CI: 1.16-3.09, P = 0.01) and individuals with rectal adenoma (OR = 2.95, 95% CI: 1.66-5.26, P = 0.0002).
  • In conclusion, variants that enhance TGFB1 production may be associated with an increased risk of advanced colorectal adenoma.
  • [MeSH-minor] Adenoma / genetics. Aged. Female. Gene Expression Regulation, Neoplastic. Genetic Variation. Genotype. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Reference Values. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615257.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


11. Neĭmark AI, Snegirev IV, Neĭmark BA: [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma]. Urologiia; 2006 Mar-Apr;(2):75, 77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma].
  • The authors analyse preoperative preparation of 91 patients with benign prostatic hyperplasia (BPH).
  • Two groups of patients received conventional preparation (group 1) and magnetotherapy (group 2) before TUR of the prostate.
  • The examination covered immune system, bacteriological indices of urine and prostatic tissue.
  • Conventional preoperative preparation fails to correct immunity, to change bacterial urine flora, to improve hemodynamics in the prostate.
  • [MeSH-major] Ferrosoferric Oxide / therapeutic use. Physical Therapy Modalities / instrumentation. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Tract Infections / prevention & control
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Leukocyte Count. Male. Perioperative Care / methods. Prostate / microbiology. Rectum. T-Lymphocytes / immunology. Urine / microbiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708596.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


12. Al'-Shukri SKh, Gorbachev AG, Borovets SIu, Belousov VIa, Kuz'min IV, Chushkin KA: [Prostatilen treatment of prostatic adenoma]. Urologiia; 2006 Nov-Dec;(6):22, 25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatilen treatment of prostatic adenoma].
  • We studied efficacy of repeated courses of prostatilen in suppositories with dimexide in prostatic adenoma patients with normal micturition.
  • This suggests possibility of suppository prostatilen use not only as an alternative for expensive drugs but also in combination with them in treatment of initial prostatic adenoma.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315707.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Peptides; 0 / Suppositories; 0 / prostatilen; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


13. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C: Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology; 2008 Feb;71(2):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial.
  • OBJECTIVES: To compare the short term outcomes of photoselective vaporization (PVP) and transurethral resection of the prostate (TURP) for glands larger than 70 mL in a prospective randomized trial.
  • METHODS: Seventy-six consecutive patients with enlarged prostatic adenomas of 70 to 100 mL were randomly assigned for surgical treatment with TURP (n = 37) or PVP (n = 39).
  • International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) scores, maximum flow rates (Qmax), postvoid urine residues (PVR), and transrectal ultrasound (TRUS) volumes were recorded.
  • [MeSH-major] Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2008 Sep;72(3):718-9 [18597826.001]
  • (PMID = 18308094.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


14. Kolbasov DN: [Hyperbaric oxygenation in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperbaric oxygenation in patients with prostatic adenoma].
  • [MeSH-major] Hyperbaric Oxygenation. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526884.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


15. Ge D, You Z: Expression of interleukin-17RC protein in normal human tissues. Int Arch Med; 2008;1(1):19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: IL-17RC expression in 51 normal human tissues and two benign tumors (i.e., lymphangioma and parathyroid adenoma) on the tissue microarrays was determined by immunohistochemical staining, using two polyclonal antibodies against IL-17RC.
  • IL-17RC protein was expressed in many cell types including the myocardial cells, vascular and lymphatic endothelial cells, glandular cells (of the adrenal, parathyroid, pituitary, thyroid, pancreas, parotid salivary, and subepidermal glands), epithelial cells (of the esophagus, stomach, intestine, anus, renal tubule, breast, cervix, Fallopian tube, epididymis, seminal vesicle, prostate, gallbladder, bronchus, lung, and skin), oocytes in the ovary, Sertoli cells in the testis, motor neurons in the spinal cord, autonomic ganglia and nerves in the intestine, skeletal muscle cells, adipocytes, articular chondrocytes, and synovial cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2078-87 [18310510.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1207-11 [18200064.001]
  • [Cites] Cytokine. 2008 Feb;41(2):92-104 [18178098.001]
  • [Cites] Cytokine. 2008 Feb;41(2):105-13 [18061473.001]
  • [Cites] Cytokine. 2008 Feb;41(2):84-91 [18039580.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):597-607 [18202747.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):124-6 [18204425.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):655-63 [18097068.001]
  • [Cites] Cytokine. 2007 Oct;40(1):35-43 [17881243.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5462-73 [17911633.001]
  • [Cites] Cytokine. 2007 Jun;38(3):157-64 [17644350.001]
  • [Cites] J Heart Lung Transplant. 2007 Jul;26(7):669-74 [17613395.001]
  • [Cites] Neoplasia. 2007 Jun;9(6):464-70 [17603628.001]
  • [Cites] Cell Res. 2007 May;17(5):435-40 [17452998.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13447-55 [17355969.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4466-72 [17372004.001]
  • [Cites] J Neuroimmunol. 2007 Feb;183(1-2):96-103 [17240458.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1372-8 [17237384.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8542-9 [17142752.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6852-8 [17082599.001]
  • [Cites] Prostate. 2006 Sep 1;66(12):1268-74 [16688746.001]
  • [Cites] J Neurosci Res. 2006 Aug 1;84(2):379-88 [16676327.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):566-73 [16785554.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):36-9 [16785495.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1685-91 [16818675.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1287-98 [16310341.001]
  • [Cites] Cell Immunol. 2005 Oct;237(2):123-30 [16386239.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):175-83 [16397230.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):711-5 [16393951.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Sep;33(3):248-53 [15901616.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):404-12 [15972674.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):560-6 [15799031.001]
  • [Cites] Immunity. 2005 Mar;22(3):285-94 [15780986.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):233-40 [15657292.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 21;326(3):624-31 [15596145.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8276-84 [15548695.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3698-704 [10446984.001]
  • [Cites] J Immunol. 1999 Jan 1;162(1):577-84 [9886435.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5483-6 [7499828.001]
  • [Cites] Immunity. 1995 Dec;3(6):811-21 [8777726.001]
  • [Cites] Immunity. 2004 Oct;21(4):467-76 [15485625.001]
  • [Cites] Joint Bone Spine. 2004 Mar;71(2):87-90 [15050191.001]
  • [Cites] Cell Mol Life Sci. 2004 Mar;61(5):567-79 [15004696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1229-34 [14742870.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50273-82 [12958313.001]
  • [Cites] Br J Pharmacol. 2003 Oct;140(4):595-610 [14504135.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33232-8 [12807873.001]
  • [Cites] Prostate. 2003 Aug 1;56(3):171-82 [12772186.001]
  • [Cites] Scand J Gastroenterol. 2003 Feb;38(2):180-5 [12678335.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Apr;14(2):155-74 [12651226.001]
  • [Cites] Gut. 2003 Jan;52(1):65-70 [12477762.001]
  • [Cites] Nat Med. 2002 May;8(5):500-8 [11984595.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4309-16 [11706037.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):170-4 [11802165.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):165-9 [11802164.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):861-8 [11777983.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6015-20 [11698482.001]
  • [Cites] Transplant Proc. 2000 Nov;32(7):1773 [11119928.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1660-4 [11058597.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19167-76 [10749887.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2799-805 [18684971.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1063-75 [18411338.001]
  • (PMID = 18928529.001).
  • [ISSN] 1755-7682
  • [Journal-full-title] International archives of medicine
  • [ISO-abbreviation] Int Arch Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2596096
  •  go-up   go-down


16. Wong-You-Cheong JJ, Woodward PJ, Manning MA, Davis CJ: From the archives of the AFIP: Inflammatory and nonneoplastic bladder masses: radiologic-pathologic correlation. Radiographics; 2006 Nov-Dec;26(6):1847-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephrogenic adenoma has no typical features, and pathologic evaluation is required for diagnosis.
  • The various types of cystitis (cystitis cystica, cystitis glandularis, and eosinophilic cystitis) require pathologic diagnosis.
  • The diagnosis of chemotherapy cystitis and radiation cystitis should be clinically evident, but imaging may be used to determine severity and to assess complications.
  • The extravesical findings allow the diagnosis to be made easily.
  • Finally, extrinsic masses arising from the prostate or distal ureter may cause filling defects, which can be confused with intrinsic bladder masses.
  • [MeSH-major] Image Enhancement / methods. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods. Urinary Bladder Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102055.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


17. Iwamoto K, Hiraoka Y, Shimizu Y: Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia. J Nippon Med Sch; 2008 Apr;75(2):77-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia.
  • OBJECTIVE: Transurethral enucleation of the prostate (TUE) is designed for complete removal of the prostate lobes.
  • On the basis of TUE and holmium laser enucleation of the prostate, we developed a new technique of transurethral detachment prostatectomy (TUDP) using a tissue morcellator.
  • MATERIALS AND METHODS: In TUDP, enucleation is performed with a prostate-detaching blade and the tip of a resectoscope, followed by removal of the tissue with a morcellator.
  • This study reports our experience with TUDP in which the weight of retrieved tissue was greater than 30 g in 76 patients with benign prostate hyperplasia.
  • RESULTS: The mean preoperative total prostate and adenoma volumes were 70.7 and 47.4 mL, respectively.
  • The mean weight of removed prostate tissue was 61.1 g.
  • The mean preoperative maximum flow rate (Qmax), International Prostate Symptom Score (IPSS), and quality of life score (QOL) improved from 9.8 mL/sec, 20.2, and 4.9, to 22.3 mL/sec, 3.1 and 1.2, respectively.
  • The mean prostate volume and serum prostate-specific antigen level measured 6 months postoperatively in 46 patients were 10.68 mL and 0.89 ng/mL, respectively.
  • CONCLUSIONS: TUDP is effective for complete removal of large prostate lobes in patients with large benign prostate hyperplasia and is associated with lower perioperative morbidity.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Organ Size. Postoperative Complications. Prostate / pathology

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18475027.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Blah M, Nouira Y, Kallel Y, Hafsia GH, Horchani A: [Bladder herniation]. Ann Chir; 2005 Dec;130(10):633-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis is frequently done during surgery.
  • Retrograde urethrocystography or computerized tomography confirm the diagnosis.
  • We report a case of bilateral inguinal hernia involving the bladder at the right side in a 87 years old man who had a surgical history of transvesical adenomectomy of the prostate.
  • The diagnosis was done on the retrograde urethrocystography.
  • [MeSH-minor] Adenoma / surgery. Aged. Functional Laterality. Humans. Male. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043116.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Kamalov AA, Efremov EA, Dorofeev SD, Paniushkin SM: [Use of oral vitaprost in the treatment of chronic abacterial prostatitis]. Urologiia; 2006 Sep-Oct;(5):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An open trial performed in 2001 by the Research Institute of Urology has demonstrated good efficacy and safety of rectal suppositoria Vitaprost, the active substance of which is a complex of water-soluble biologically active peptides isolated from bovine prostate, in combined treatment of chronic bacterial and abacterial prostatitis in patients of all ages including those with concomitant adenoma.
  • Current comparative clinical trial has shown that Vitaprost tablets in combination with nonsteroid anti-inflammatory drugs effectively treat prostatic inflammation in patients with chronic abacterial prostatitis, produce more potent and stable effect than monotherapy with ketonal.

  • Genetic Alliance. consumer health - Prostatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444152.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Peptides; 90Y4QC304K / Ketoprofen
  •  go-up   go-down


20. Vogel LK, Saebø M, Skjelbred CF, Abell K, Pedersen ED, Vogel U, Kure EH: The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer; 2006 Jul 04;6:176
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
  • The aim of this study has been to determine the ratio of matriptase to HAI-1 mRNA expression in affected and normal tissue from individuals with colorectal cancer adenomas and carcinomas as well as in healthy individuals, in order to determine at which stages a dysregulated ratio of matriptase/HAI-1 mRNA is present during carcinogenesis.
  • In accordance with this, the matriptase mRNA level was also lower in adenomas/carcinomas combined as compared to their adjacent normal tissue (p < 0.01).
  • Both adenomas and carcinomas displayed a significantly different matriptase/HAI-1 mRNA ratio than corresponding normal tissue from healthy control individuals (p < 0.05).
  • In addition statistically significant difference (p < 0.001) could be observed between mild/moderate and severe adenomas and their adjacent normal tissue.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colorectal Neoplasms / metabolism. Membrane Glycoproteins / metabolism. Serine Endopeptidases / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6202-7 [16273651.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):728-35 [15471558.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6370-6 [9045658.001]
  • [Cites] Immunogenetics. 1999 May;49(5):420-8 [10199918.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18231-6 [10373424.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11054-61 [10500122.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26333-42 [10831593.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36720-5 [10962009.001]
  • [Cites] Tumour Biol. 2001 Mar-Apr;22(2):104-14 [11125283.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1301-11 [11290548.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10539-46 [11792696.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1101-7 [11948120.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3765-79 [12032844.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):37637-46 [12149247.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1101-5 [12615728.001]
  • [Cites] Expert Rev Mol Diagn. 2003 May;3(3):331-8 [12779007.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):635-42 [12825872.001]
  • [Cites] Biochem J. 2003 Aug 1;373(Pt 3):689-702 [12744720.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1898-904 [14584072.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):901-10 [14638864.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):890-6 [14713848.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11 [14734471.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5687-98 [15964823.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):626-33 [16021568.001]
  • [Cites] Genes Dev. 2005 Aug 15;19(16):1934-50 [16103220.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):228-35 [15368474.001]
  • (PMID = 16820046.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / RNA, Messenger; 0 / SPINT1 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.109 / ST14 protein, human
  • [Other-IDs] NLM/ PMC1525198
  •  go-up   go-down


21. Tong GX, Melamed J, Mansukhani M, Memeo L, Hernandez O, Deng FM, Chiriboga L, Waisman J: PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol; 2006 Mar;19(3):356-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2: a reliable marker for nephrogenic adenoma.
  • Nephrogenic adenoma is a rare lesion of the urinary tract.
  • The diagnosis usually is straightforward when characteristic microscopic and clinical findings are present, and the entity is familiar.
  • However, misdiagnosis, in particular of adenocarcinoma of the prostate gland, may occur.
  • It recently was demonstrated that nephrogenic adenoma in renal transplant patients originated from the renal tubular epithelium.
  • This newly proved, but long sought information may be helpful in the differential diagnosis of nephrogenic adenoma.
  • In this study, we investigated the expression of a renal transcription factor, PAX2, in 39 nonrenal transplant-related nephrogenic adenomas, 100 adenocarcinomas of the prostate gland, and 47 urothelial carcinomas of the urinary tract.
  • A strong and distinct nuclear staining of PAX2 was found in all 39 cases of nephrogenic adenoma (100%), but not in normal prostate tissue, normal urothelium, adenocarcinomas of the prostate gland, and invasive urothelial carcinomas.
  • Focal CD10 was detected in six of 13 nephrogenic adenomas in the superficial papillary component and in normal prostate epithelium, normal urothelium, lymphocytes, adenocarcinoma of the prostate gland, and urothelial carcinoma.
  • There was no uroplakins detected in nephrogenic adenoma.
  • Therefore, these findings are suggesting that nephrogenic adenoma in nonrenal transplant patients may also arise from the renal epithelium, as did the comparable lesions after transplantation.
  • PAX2 is a specific and sensitive immunohistochemical marker in identification and differential diagnosis of nephrogenic adenoma.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. PAX2 Transcription Factor / analysis. Urologic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Male. Middle Aged. Neprilysin / analysis. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400326.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


22. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y: Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci; 2010 May;101(5):1286-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
  • Adipocytokines are adipocyte-secreted hormones associated with some malignancies such as colorectal, breast, and prostate cancer.
  • We hypothesized that changes in the levels of adipocytokines may indicate the carcinogenesis and progression of colorectal cancer and adenoma, and investigated the association of the blood levels of several adipocytokines through a case-control study.
  • Blood levels of adiponectin, leptin, resistin, visfatin, and C-peptide at diagnosis were measured in 115 colorectal cancer patients and 115 age-, sex-, and body mass index-matched controls.
  • The same analysis was performed in 72 colorectal adenoma patients and 72 controls.
  • The adiponectin level in adenoma patients was significantly lower than that of controls on multivariate analysis (P = 0.04).
  • Its level was inversely correlated with the number of adenoma (P = 0.02), but not correlated with the size of adenoma.
  • Adiponectin level may be a good biomarker of colorectal adenoma.
  • [MeSH-major] Adenoma / blood. Adipokines / blood. Biomarkers, Tumor / blood. Colorectal Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331631.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Biomarkers, Tumor; 0 / C-Peptide; 0 / Cytokines; 0 / Leptin; 0 / RETN protein, human; 0 / Resistin; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  •  go-up   go-down


23. Desai MM, Aron M, Canes D, Fareed K, Carmona O, Haber GP, Crouzet S, Astigueta JC, Lopez R, de Andrade R, Stein RJ, Ulchaker J, Sotelo R, Gill IS: Single-port transvesical simple prostatectomy: initial clinical report. Urology; 2008 Nov;72(5):960-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: To present the initial report of single-port transvesical enucleation of the prostate in 3 patients with large-volume benign prostatic hyperplasia.
  • METHODS: Single-port transvesical enucleation of the prostate was performed in 3 patients with large-volume (187, 93, and 92 g) benign prostatic hyperplasia.
  • After establishing pneumovesicum, the adenoma was enucleated in its entirety transvesically under laparoscopic visualization using standard and articulating laparoscopic instrumentation.
  • The adenoma was extracted through the solitary skin and bladder incision after bivalving the prostate lobes within the bladder.
  • RESULTS: Single-port transvesical enucleation of the prostate was technically feasible in all 3 cases.
  • Additional experience at our and other institutions is necessary to determine its role in the surgical management of large-volume symptomatic benign prostatic hyperplasia.
  • [MeSH-major] Adenoma / surgery. Prostatectomy / methods. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2009 Jun;73(6):1425-6; author reply 1426 [19482165.001]
  • (PMID = 18835633.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Talmant V, Esposito P, Stilhart B, Mohr M, Tranchant C: [Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report]. Rev Neurol (Paris); 2006 Mar;162(3):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He developed severe urinary disorders increased by a prostatic adenoma which led to surgical treatment.
  • [MeSH-minor] Adenoma / surgery. Antiparkinson Agents / therapeutic use. Biomarkers. Brain / pathology. Brain Chemistry. Combined Modality Therapy. Diagnostic Errors. Disease Progression. Fatal Outcome. Humans. Levodopa / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Parkinson Disease / diagnosis. Parkinson Disease / drug therapy. Parkinson Disease / therapy. Prostatectomy. Prostatic Neoplasms / surgery. Substantia Nigra / pathology. Ubiquitin / analysis. alpha-Synuclein / analysis

  • Genetic Alliance. consumer health - Multiple system atrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585892.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; Clinical Conference; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Biomarkers; 0 / Ubiquitin; 0 / alpha-Synuclein; 46627O600J / Levodopa
  •  go-up   go-down


25. Shaked G, Czeiger D: Distended urinary bladder and diverticulum-a rare cause of large-bowel obstruction. Am J Surg; 2009 Feb;197(2):e23-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Later the patient underwent surgery to remove an enlarged benign prostatic adenoma, which was the underlying cause of the bladder distention.
  • [MeSH-major] Dilatation, Pathologic / etiology. Diverticulum / complications. Intestinal Obstruction / etiology. Prostatic Hyperplasia / complications. Urinary Bladder Diseases / etiology


26. Sotelo R, Clavijo R, Carmona O, Garcia A, Banda E, Miranda M, Fagin R: Robotic simple prostatectomy. J Urol; 2008 Feb;179(2):513-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Minimally invasive approaches for large, symptomatic benign prostatic hyperplasia are replacing the gold standard open surgical approach, duplicating its results with lower morbidity.
  • Considerable improvement from baseline was noted in International Prostate Symptom Score (preoperative vs postoperative 22 vs 7.25) and maximum urine flow (preoperative vs postoperative 17.75 vs 55.5 ml per minute).
  • Further publications are expected with larger series and larger prostatic adenomas.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Oct;180(4):1569-70; author reply 1570 [18718613.001]
  • (PMID = 18076926.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Józsa LG: Histologic diagnoses of tissues from two nineteenth century Habsburgs. Paleopathol Newsl; 2008 Mar;(141):12-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gout (urate nephropathy), severe arteriosclerosis, prostate adenoma and purulent prostatitis could also be diagnosed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831390.001).
  • [ISSN] 0148-4737
  • [Journal-full-title] Paleopathology newsletter
  • [ISO-abbreviation] Paleopathol Newsl
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Habsburg J; Romanova AP
  •  go-up   go-down


28. Passavanti G, Pizzuti V, Bragaglia A, Mengoni F, Costantini FM, Paolini R: [The use of bipolar PlasmaKinetic resectoscope in endoscopic resection of the prostate: our experience]. Urologia; 2007 Jul-Sep;74(3):160-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of bipolar PlasmaKinetic resectoscope in endoscopic resection of the prostate: our experience].
  • Prostatic endoscopic resection (TURP) is a reference method in the treatment of prostatic obstruction.
  • 20 patients underwent bipolar plasmakinetic resection of the prostate.
  • Their age ranged between 58 yrs and 82 yrs (av.: 70.2 yrs), the adenoma volume, checked with TR ultrasound scanning, was between 33 and 44 cc (av.: 37.6), the Qmax was between 6.4 and 9.0 mL/min (av.: 7.42 mL/min).
  • The use of the new technologies in prostatic endoscopic resection has allowed us to improve the efficacy of such a method.
  • Above all, the use of a bipolar electrosurgical knife enables us to associate a basal hemostasis with the resection of the prostatic tissue.
  • We have been able, in our experience, to assess that this technology represents a useful guarantee to improve the results of prostatic endoscopic resection.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086395.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Giovannucci E, Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology; 2007 May;132(6):2208-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.
  • Recent evidence indicates that obesity and related metabolic abnormalities are associated with increased incidence or mortality for a number of cancers, including those of the colon, prostate, and pancreas.
  • Obesity, physical inactivity, visceral adiposity, hyperglycemia, and hyperinsulinemia are relatively consistent risk factors for colon cancer and adenoma.
  • For prostate cancer, the relationship to obesity appears more complex.
  • Obesity seems to contribute to a greater risk of aggressive or fatal prostate cancer but perhaps to a lower risk of nonaggressive prostate cancer.
  • Furthermore, men with type 2 diabetes mellitus are at lower risk of developing prostate cancer.
  • [MeSH-major] Colonic Neoplasms / physiopathology. Diabetes Mellitus, Type 2 / complications. Obesity / complications. Pancreatic Neoplasms / physiopathology. Prostatic Neoplasms / physiopathology


30. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy]. Urologiia; 2007 Mar-Apr;(2):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy].
  • [MeSH-major] Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Serenoa / chemistry

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578203.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 33
  •  go-up   go-down


31. Verger-Kuhnke AB, Reuter MA, Epple W, Ungemach G, Beccaría ML: [Photoselective vaporization with the 80-watt KTP-laser (kalium-titanyl-phosphate) and low-hydraulic-pressure TURP in the treatment of BPH: our experience with 230 cases]. Arch Esp Urol; 2007 Mar;60(2):167-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La vaporizacion fotoselectiva de la HPB con el KTP-laser (kalium- titanyl-phosphat) de 80 watt y la RTU-P de baja presion hidraulica, experiencia en 230 casos.
  • The additional Resection was carried out in those patients with great adenomas or having a big middle lobe.
  • The group 1 (n: 50) just by laser treatment and small adenomas, the haemoglobin was reduced a 3.2% and nobody required a transfusion.
  • Group 2 (n: 180) with combined treatment of KTP-laser and TUR-P in great adenomas, the haemoglobin was reduced in average 13.7% after the intervention; 2 patients (1.1%) needed a transfusion.
  • CONCLUSION: Our study shows the advantages of combining both, the advantages to combine both surgical procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Laser Therapy / instrumentation. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484484.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Phosphates; 12690-20-9 / potassium titanylphosphate; D1JT611TNE / Titanium
  •  go-up   go-down


32. Traore CB, Kamate B, Toure ML, Diarra T, Bayo S: [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases]. Mali Med; 2006;21(4):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases].
  • [Transliterated title] Aspects anatomopathologiques, cliniques et radiologiques des tumeurs benignes de la prostate au Mali, a propos de 759 cas.
  • The benign prostate tumours are dominated by prostatic adenomyoma.
  • The objective of this work is to describe the anatomo-pathological, clinical and radiological aspects of benign prostate tumours in Mali.
  • It has involved 759 patients who had histological confirmed prostate adenoma in the Department of Urology in Point G University Hospital.
  • The patients were classified according to age, the clinical exam, the rate of prostate specific antigen (PSA), the sonogram, the macro and microscopic exam.
  • The apical part of the prostate is the area mostly involved.
  • "The night pollakiuria" was the primarily clinical sign in all patients; the prostate specific antigen (PSA) is high among more than 80%.
  • [MeSH-major] Adenomyoma / pathology. Adenomyoma / radiography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiography. Urology Department, Hospital / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Hospitals, University. Humans. Incidence. Male. Mali / epidemiology. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437843.001).
  • [ISSN] 0464-7874
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


33. Ergakov DV, Martov AG, Maksimov VA: [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit]. Urologiia; 2009 Jan-Feb;(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
  • We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate.
  • Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions).
  • [MeSH-major] Phytotherapy. Plant Preparations / administration & dosage. Postoperative Care. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432230.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


34. Pushkar' DIu, belousov IuB, Dukhanin AS, Maneshina OA, Govorov AV, Kurdzhiev MA: [Interaction of omnic (tamsulozine) and its generic analogues with alpha-adrenoreceptors]. Urologiia; 2009 Sep-Oct;(5):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In current practice of pharmacotherapy of prostatic adenoma alpha1-adrenoblockers are first-line drugs the efficacy and safety of which have been proved in many randomized studies.
  • Because of the appearance of a large amount of generic analogues of tamsulozine on the market we studied the ability of tamsulozine analogues to bind with alpha-adrenoreceptors on rat and human prostate affected by adenoma.
  • [MeSH-major] Adenoma / metabolism. Adenoma / microbiology. Adrenergic alpha-Antagonists / pharmacokinetics. Drugs, Generic / pharmacokinetics. Prostate / metabolism. Receptors, Adrenergic, alpha / metabolism. Sulfonamides / pharmacokinetics

  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209868.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Drugs, Generic; 0 / Receptors, Adrenergic, alpha; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


35. Malek RS: [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma]. Urologiia; 2006 Sep-Oct;(5):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma].
  • Novel laser technologies were used in development of a new highly effective and simple method of laser adenomectomy (LA) called photoselective vaporization of the prostate (PVP).
  • Efficacy of PVP is comparable to transurethral resection (TUR) of prostatic adenoma but is more cost-effective than TUR or other low-invasive techniques.
  • Therefore, PVP is very promising in surgical treatment of obstructive prostatic adenoma and may become a leading surgical method in this disease.
  • [MeSH-major] Laser Therapy. Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Animals. Humans. Male. Phosphates. Potassium Compounds. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIPOTASSIUM PHOSPHATE .
  • Hazardous Substances Data Bank. MONOPOTASSIUM DIHYDROGEN PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444145.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Phosphates; 0 / Potassium Compounds; 16068-46-5 / potassium phosphate
  •  go-up   go-down


36. Mucha SA, Meleń-Mucha G, Godlewski A, Stepień H: Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch; 2007 Mar;450(3):335-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the significance of matrix metalloproteinases (MMPs) for tumor growth and angiogenesis, we have studied the effect of batimastat (BB-94), a synthetic MMPs inhibitor (MMPI) on the progression of prolactin-secreting pituitary adenoma in rats.
  • The ability of BB-94 to suppress established pituitary tumor growth suggests a possible application of MMPIs in the treatment of pituitary adenomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1999 Dec;45(6):1432-40; discussion 1440-1 [10598711.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2931-5 [10946906.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5356-64 [10537320.001]
  • [Cites] Prostate. 1998 Jun 1;35(4):248-54 [9609547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(14):4549-53 [6589610.001]
  • [Cites] Invest New Drugs. 1996;14(2):193-202 [8913840.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2087-91 [8347186.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Aug;7(2):120-5 [1497900.001]
  • [Cites] Nature. 1987 Apr 2-8;326(6112):515-7 [2882423.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):176-82 [9858503.001]
  • [Cites] Endocr Pathol. 2000 Winter;11(4):341-352 [12114758.001]
  • [Cites] Drugs. 2000 May;59(5):1043-55 [10852638.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):263-9 [10634397.001]
  • [Cites] Endocrine. 1999 Dec;11(3):217-33 [10786818.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3615-9 [9858948.001]
  • [Cites] Mol Cell Endocrinol. 1996 Nov 29;124(1-2):33-42 [9027322.001]
  • [Cites] FASEB J. 1991 May;5(8):2145-54 [1850705.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2528-33 [9059343.001]
  • [Cites] Am J Anat. 1987 Aug;179(4):315-23 [3661455.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):259-272 [12114787.001]
  • [Cites] Prostate. 2000 May 1;43(2):77-82 [10754522.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):45-53 [8690524.001]
  • [Cites] J Endocrinol. 1996 Jul;150(1):99-106 [8708569.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 18;87(20):1546-50 [7563189.001]
  • [Cites] J Surg Res. 1997 May;69(2):367-71 [9224409.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):27-34 [7705930.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):460-4 [8050828.001]
  • [Cites] Ann Oncol. 1995 Dec;6(10):967-74 [8750146.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):733-44 [3095506.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):353-65 [10909428.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] Cell Res. 1998 Sep;8(3):171-7 [9791730.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1089-94 [8496297.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):205-8 [8431353.001]
  • [Cites] Endocrinology. 1981 Nov;109(5):1700-7 [7297500.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):293-8 [7535861.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4726-8 [8062271.001]
  • [Cites] Neuroendocrinology. 1983 Jul;37(1):23-31 [6888657.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 17235567.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Estrogens; 0 / Proliferating Cell Nuclear Antigen; 0 / Protease Inhibitors; 0 / Thiophenes; 47E5O17Y3R / Phenylalanine; 731DCA35BT / Diethylstilbestrol; BK349F52C9 / batimastat; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


37. Zhang Y, Du CJ, Xu G, Chen JM, Jing X: [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g]. Zhonghua Nan Ke Xue; 2007 Dec;13(12):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g].
  • OBJECTIVE: To evaluate the effect of transurethral holmium laser enucleation of the prostate (HoLEP) for prostate adenoma greater than 100 g.
  • METHODS: Sixty BPH patients with the prostate larger than 100 g were randomized to two treatment groups of HoLEP (n = 32) and open prostatectomy (n = 28).
  • Comparisons were made between the two groups in operating time, blood loss, bladder irrigating time, catheterization time and hospital stay, as well as in the international prostate symptom score (IPSS), quality of life (QOL) score, maximum urinary flow rate (Qmax) and postvoid residual volume (PVR) before and 3 months after the surgery.
  • CONCLUSION: HoLEP and open prostatectomy are equally effective procedures for removal of large prostate adenomas, but the former is a better surgical option for prostate adenomas larger than 100 g for its greater safety, less pain and faster recovery.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284057.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  •  go-up   go-down


38. Lepage JY, Rivault O, Karam G, Malinovsky JM, Le Gouedec G, Cozian A, Malinge M, Pinaud M: [Anaesthesia and prostate surgery]. Ann Fr Anesth Reanim; 2005 Apr;24(4):397-411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaesthesia and prostate surgery].
  • [Transliterated title] Anesthésie et chirurgie de la prostate.
  • OBJECTIVES: To review the current data about anaesthetic management in prostate surgery with special regards on analysis and prevention of specific risks, appropriate anaesthetic procedure keeping with surgery and patient, recognition and treatment of adverse events.
  • Preoperative evaluation of cardiovascular, respiratory, neurological and metabolic comorbidity is a source of prognostic information and an essential tool in the management of elderly patients with prostate disease.
  • Extreme patient positioning applied in prostate surgery induces haemodynamic and respiratory changes and are associated with severe muscular and nervous injuries.
  • Whether open transvesical or transurethral prostatectomy for treatment of benign hypertrophy depends on the size of the gland: transurethral resection is safe up to 80 g.
  • Intrathecal anaesthesia with a T9 cephalad spread of sensory block, produces adequate conditions for transurethral prostatectomy and allows a rapid diagnosis of irrigating fluid absorption syndrome.
  • In spite of recommended preoperative antibiotic prophylaxis, bacteriemias are frequent during transurethral prostate resection.
  • [MeSH-major] Anesthesia. Prostate / surgery. Urogenital Surgical Procedures
  • [MeSH-minor] Adenoma / surgery. Humans. Intraoperative Complications / epidemiology. Intraoperative Complications / prevention & control. Male. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Preoperative Care. Prostatectomy / adverse effects. Prostatic Neoplasms / surgery. Risk Factors

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15826790.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 186
  •  go-up   go-down


39. Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S, Yeager M, Welch B, Pinsky P, Weissfeld J, Hayes RB: GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1823-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma.
  • Cigarette smoking is a risk factor for colon adenoma.
  • We examined the prevalence of GSTM1 and GSTT1 gene deletions, and two GSTP1 polymorphisms in 772 cases with advanced colorectal adenomas (>1 cm, villous elements or high-grade dysplasia) of the distal colon (descending or sigmoid colon or rectum) and 777 sigmoidoscopy negative controls enrolled in the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • Advanced adenoma risk was increased in current/former smokers (OR, 1.4; 95% CI, 1.2-1.8).
  • In summary, this is the first study to report associations between colorectal adenomas and GSTM1 wild-type and GSTT1 null allele among smokers.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030123.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


40. Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB: Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms. J Cutan Pathol; 2010 Apr;37(4):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMACR has been established as a valuable diagnostic marker for prostate cancer and has recently been shown to be useful in the diagnosis of colorectal carcinoma.
  • METHODS: Five samples of normal sebaceous glands as well as five cases each of sebaceous hyperplasia (SH), sebaceous adenoma (SA), basal cell carcinoma (BCC) with sebaceous differentiation and extraocular sebaceous carcinoma (SC) were evaluated for immunohistochemical (IHC) expression of AMACR.
  • CONCLUSIONS: The expression of AMACR is increased in benign sebaceous glands and SH; with decreasing AMACR expression in tumors with less sebaceous differentiation (i.e.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Racemases and Epimerases / metabolism. Sebaceous Gland Neoplasms / enzymology. Sebaceous Glands / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638170.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


41. Krambeck AE: Evolution and success of holmium laser enucleation of the prostate. Indian J Urol; 2010 Jul;26(3):404-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution and success of holmium laser enucleation of the prostate.
  • AIMS: The purpose of this article is to review the development of instruments, current technique, and expected outcomes for holmium laser enucleation of the prostate (HoLEP).
  • RESULTS: Historically, the gold-standard management for symptomatic obstructing benign prostatic hyperplasia (BPH) has been transurethral resection of the prostate (TURP).
  • Laser treatment of BPH has evolved from coagulation to complete adenoma enucleation.
  • The holmium laser was initially utilized for prostate ablation and soon evolved into holmium laser tissue resection, but was limited by difficulties with extracting the prostate tissue from the bladder.
  • With the development of a compatible tissue morcellator whole prostate lobes could be enucleated similar to an open prostate enucleation and the HoLEP procedure was developed.
  • Changes in enucleation technique have also increased the efficiency of the HoLEP procedure, such that any sized prostate can be treated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21116363.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2978443
  • [Keywords] NOTNLM ; Benign prostatic hyperplasia / holmium laser / prostate enucleation
  •  go-up   go-down


42. Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C: Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS One; 2010;5(3):e9472
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Parathyroid adenomas constitute the most common entity in primary hyperparathyroidism, and although recent advances have been made regarding the underlying genetic cause of these lesions, very little data on epigenetic alterations in this tumour type exists.
  • In this study, we have determined the levels of promoter methylation regarding the four tumour suppressor genes APC, RASSF1A, p16(INK4A) and RAR-beta in parathyroid adenomas.
  • Hypermethylation of p16(INK4A) was demonstrated in a single adenoma, whereas RAR-beta hypermethylation was not observed in any sample.
  • [MeSH-minor] Adenoma / metabolism. CpG Islands. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Epigenesis, Genetic. Gene Expression Profiling. Genotype. Humans. Long Interspersed Nucleotide Elements. Parathyroid Glands / metabolism. Receptors, Retinoic Acid / metabolism

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3663-7 [8855819.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2627-30 [9709922.001]
  • [Cites] Kidney Int. 1999 Apr;55(4):1375-83 [10201002.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3775-80 [10523029.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):37-43 [15375009.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):612-20 [15632063.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5052-60 [15923622.001]
  • [Cites] Cell. 2006 Apr 21;125(2):327-41 [16630820.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):509-23 [16728578.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):109-16 [16893590.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):338-44 [17047023.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):125-34 [17395981.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):501-12 [17639063.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):595-600 [18203293.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2551-9 [18451216.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):609-21 [18509008.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4038-44 [18593979.001]
  • [Cites] Int J Oncol. 2008 Oct;33(4):861-9 [18813801.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1954-6 [18385753.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1735-42 [18841156.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17420-5 [18987311.001]
  • [Cites] Exp Mol Pathol. 2008 Dec;85(3):201-6 [18977219.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8 [19033568.001]
  • [Cites] Mol Cancer Res. 2008 Dec;6(12):1894-907 [19074834.001]
  • [Cites] Int J Cancer. 2009 Mar 1;124(5):1122-32 [19058182.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):481-92 [19148484.001]
  • [Cites] Prostate. 2009 Nov 1;69(15):1643-50 [19623543.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1998-2004 [11448917.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3663-6 [12097272.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4010-4 [15217932.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):643-5 [1310068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4452-6 [1316610.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1317-21 [7962323.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):1736-9 [8626826.001]
  • [Cites] Genomics. 1997 Aug 15;44(1):94-100 [9286704.001]
  • (PMID = 20208994.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2830427
  •  go-up   go-down


43. Parma P, Dall'Oglio B, Samuelli A, Bondavalli C, Bellomi A: [Laparoscopic removal of voluminous right seminal vesicle neoplasm]. Urologia; 2010 Oct-Dec;77 Suppl 17:46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Asportazione laparoscopica di voluminosa neoplasia della vescicola seminale destra.
  • The diagnosis was achieved by transrectal ultrasound, CT of the abdomen and pelvis, and biopsy of both prostate and seminal vesicle.
  • [MeSH-minor] Adenoma / complications. Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adnexal Diseases / complications. Adnexal Diseases / diagnosis. Adnexal Diseases / pathology. Adnexal Diseases / surgery. Biopsy. Diagnosis, Differential. Hemospermia / etiology. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Vas Deferens / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308675.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Wolffian tumor
  •  go-up   go-down


44. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol; 2006 Mar;13(3):303-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
  • Gonadotropin-releasing hormone (GnRH) agonists have become the treatment of choice for locally advanced and metastatic prostate cancer.
  • We report a case of prostate cancer in which this treatment led to severe symptoms of intracranial hypertension due to the concomitant presence of an asymptomatic functional pituitary adenoma.
  • The histopathological examination revealed an invasive gonadotroph pituitary adenoma.
  • Two years later, there is no sign of progression either on his prostatic disease (prostate-specific antigen of 0.21 ng/mL) or on his pituitary disease (FSH, 4.7 UI/L, LH, 3.1 UI/L and total testosterone, 627 ng/dL) with values of the hypothalamic-pituitary axis in the normal range.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / diagnosis. Antineoplastic Agents, Hormonal / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Leuprolide / therapeutic use. Neoplasms, Multiple Primary. Pituitary Neoplasms / diagnosis. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643633.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


45. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER: Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):586-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of prostate cancer in a randomized clinical trial of calcium supplementation.
  • BACKGROUND: In some studies, high calcium intake has been associated with an increased risk of prostate cancer, but no randomized studies have investigated this issue.
  • METHODS: We randomly assigned 672 men to receive either 3 g of calcium carbonate (1,200 mg of calcium), or placebo, daily for 4 years in a colorectal adenoma chemoprevention trial.
  • Serum samples, collected at randomization and after 4 years, were analyzed for 1,25-(OH)2 vitamin D, 25-(OH) vitamin D, and prostate-specific antigen (PSA).
  • We used life table and Cox proportional hazard models to compute rate ratios for prostate cancer incidence and generalized linear models to assess the relative risk of increases in PSA levels.
  • RESULTS: After a mean follow-up of 10.3 years, there were 33 prostate cancer cases in the calcium-treated group and 37 in the placebo-treated group [unadjusted rate ratio, 0.83; 95% confidence interval (95% CI), 0.52-1.32].
  • CONCLUSION: In this randomized controlled clinical trial, there was no increase in prostate cancer risk associated with calcium supplementation and some suggestion of a protective effect.
  • [MeSH-major] Adenoma / prevention & control. Antacids / adverse effects. Antacids / therapeutic use. Calcium Carbonate / adverse effects. Calcium Carbonate / therapeutic use. Colorectal Neoplasms / prevention & control. Prostatic Neoplasms / etiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM CARBONATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767334.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37287; United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA42710
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antacids; 0 / Placebos; 1406-16-2 / Vitamin D; H0G9379FGK / Calcium Carbonate
  •  go-up   go-down


46. Pavlov VN, Kazikhinurov AA, Ishemgulov RR, Mustafin AT: [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method]. Urologiia; 2008 Jan-Feb;(1):31-2, 34-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method].
  • To determine microcirculation in the wall of the urinary bladder in prostatic adenoma, we used a laser analyzer of capillary circulation LAKK-01.
  • Two groups participated in the trial: 105 males with stage II prostatic adenoma (the study group) and 25 volunteers (the control group).
  • In stage II prostatic adenoma the above microcirculation decreased to a subcritical perfusion level.
  • Significantly earlier and complete recovery of microcirculation was observed in patients who had taken cardura (Pfizer) in a dose 2 mg/day for 3 months after transurethral resection of prostatic gland.
  • Thus, 2 mg/day cardura (Pfizer) in patients with prostatic adenoma of stage II after TUR of the prostate promotes early and effective recovery of microcirculation.
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Recovery of Function. Urinary Bladder / blood supply

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649676.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; NW1291F1W8 / Doxazosin
  •  go-up   go-down


47. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry in diagnostic surgical pathology of the prostate.
  • Immunohistochemistry (IHC) can play an important role in diagnostic surgical pathology of the prostate.
  • Basal cell markers, such as the 34betaE12 antibody and antibodies directed against cytokeratin 5 and 6 or p63, are very useful for demonstration of basal cells as their presence argues against a diagnosis of invasive prostatic carcinoma (PC).
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • Alpha-methylacyl-coenzyme-A racemase (AMACR) is a sensitive marker of PC (except for a few uncommon variants: atrophic, foamy gland, and pseudohyperplastic variants), and its detection by immunohistochemical staining in atypical prostatic lesions can be very useful in confirming an impression of adenocarcinoma.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • 34betaE12, p63, thrombomodulin, and uroplakin III are additional urothelial associated markers useful in this differential diagnosis.
  • PSA and PSAP immunohistochemical stains are valuable in confirming metastatic carcinoma as being of prostatic origin and should always be utilized in the diagnostic evaluation of metastatic adenocarcinoma of unknown primary origin in males.
  • [MeSH-major] Carcinoma / diagnosis. Immunohistochemistry. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis


48. Byun SS, Jeong H, Jo MK, Lee E: Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men? Urology; 2005 Sep;66(3):593-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
  • OBJECTIVES: To investigate the high prevalence of lower urinary tract symptoms in Korean men with a small prostate, we studied the proportions of histologic components of prostatic adenoma in patients with symptomatic benign prostatic hyperplasia.
  • METHODS: Prostatic adenoma specimens were obtained from men with symptomatic benign prostatic hyperplasia who underwent open prostatectomy or transurethral resection of the prostate.
  • Patients were divided into three groups according to the prostate volume as measured by preoperative transrectal ultrasonography (group 1, 20 to 40 cm3, 21 men; group 2, 41 to 80 cm3, 22 men; and group 3, greater than 80 cm3, 23 men).
  • The proportion of the stroma in the prostatic adenoma and the proportions of smooth muscle, collagen types I, II, III, and V, fibronectin, and laminin in stromal tissue were determined using automatic image analyzer quantitatively.
  • RESULTS: The proportions of the stroma in the prostatic adenoma specimens of groups 1 and 2 were significantly greater than in group 3 (P < 0.05).
  • The relative smooth muscle proportion in the prostatic adenoma (proportion of stroma x proportion of smooth muscle in stromal tissue) in groups 1 and 2 was significantly greater than in group 3 (P < 0.05).
  • CONCLUSIONS: These results suggest that the dynamic component of bladder outlet obstruction, which is mediated by smooth muscle tone, may play a more important role in the development of symptomatic benign prostatic hyperplasia in Korean men.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140084.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Razumov SV, Egorov AA: [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
  • A total of 58 patients with prostatic adenoma (PA) treated with prostamol Uno in combination with tamsulosin were divided into two groups: 28 patients continued the above combined therapy, 30 patients were switched to monotherapy with prostamol Uno.
  • All the patients were examined in the course of 4 visits according to standard protocol requesting information on the disease history, complaints, digital rectal examination, IPSS questionnaire, QOL, uroflowmetry with test for residual urine, transrectal ultrasonography of the prostate, blood test for PSA.
  • To the end of treatment month 9 the size of the prostate diminished by 6.7 cm3, on the average, in both groups.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists. Plant Extracts. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724829.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


50. Sevriukov FA, Puchkin AB, Krupin VN, Chebykin AV, Sorokin DA, Karpukhin IV, Malinina OIu, Zorin DG: [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases]. Urologiia; 2007 May-Jun;(3):28-32, 35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases].
  • Surgical interventions were made in 175 patients aged 23-87 years (mean age 64.8 years) with different diseases of the lower urinary tract (adenoma, prostatic cancer, cancer of the urinary bladder, etc.) with application of a new generation of endoscopic technique--transurethral resection in saline (TURis system) with a generator UES-40 SurgMaster (Olympus).
  • The size of the prostate in prostatic adenoma ranged from 4.8 to 121 cm3 (mean 62.5 cm3), residual urine--92.3 ml (42.6 to 310.2 ml).
  • Mean amount of the resected tissue in sclerosis of urinary bladder cervix was 7 g (5-11 g), in prostatic adenoma--41 g (10-85 g), prostatic cancer--27 g (17-49 g).
  • Incontinence was observed in 7 (5.3%) patients after removal of urethral catheter, in 5 (3.8%) patients it stopped spontaneously to the time of discharge from the hospital, 2 (1.5%) patients with prostatic cancer retained partial orthostatic incontinence.
  • Standard time limitation for transurethral resection (60-90 min) becomes insignificant in using isotonic irrigation allowing urologists to resect safely larger adenomas than it was possible earlier.
  • [MeSH-major] Electrosurgery / methods. Prostatic Diseases / surgery. Urinary Tract / surgery. Urologic Diseases / surgery. Urologic Surgical Procedures, Male / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Transurethral Resection of Prostate / instrumentation. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724828.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


51. Neĭmark AI, Isaenko VI, Iakovets IaV, Simashkevich AV, Aliev RT: [Administration of afala preparation in urological practice]. Urologiia; 2009 May-Jun;(3):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination.
  • Afala is indicated for prophylaxis in patients with initial stage of prostatic adenoma and as an alternative to expectation policy.
  • [MeSH-major] Antibodies / therapeutic use. Prostate / drug effects. Prostatic Hyperplasia / drug therapy. Urination Disorders / prevention & control
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / immunology. Quality of Life. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673125.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies; 0 / afala; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


52. Boroian RR: [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma].
  • To determine prognostic factors of lower urinary tract symptoms progression because of prostatic adenoma (PA), we studied content of the basic fibroblast growth factor (bFGF) in blood serum of patients with PA in enzyme immunoassay.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Enzyme Inhibitors / administration & dosage. Fibroblast Growth Factor 2 / blood. Finasteride / administration & dosage. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248600.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 103107-01-3 / Fibroblast Growth Factor 2; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


53. Miller AM: [The experience in postoperative administration of alpha-adrenoblockers]. Urologiia; 2007 Sep-Oct;(5):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study of efficacy of alpha-blocker alfuzosine (dalphaz CP) in a dose 10 mg/day for treatment of postoperative complications after transurethral resection (TUR) of the prostate and open adenomectomy (OAE) and in quality of life (QoL) improvement enrolled 22 patients after TUR of the prostate and 18 patients after OAE.
  • Administration of alpha-blocker on day 1 after surgical treatment of prostatic adenoma leads to earlier regress of urination disorders.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Quinazolines / therapeutic use. Transurethral Resection of Prostate. Urination Disorders / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254227.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 90347YTW5F / alfuzosin
  •  go-up   go-down


54. Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H: Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen &gt;10 ng/ml and prior negative peripheral zone biopsy? Scand J Urol Nephrol; 2005;39(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
  • OBJECTIVES: To evaluate the importance of transition zone (TZ) biopsy in benign prostatic hyperplasia (BPH) patients with serum prostate-specific antigen (PSA) >10 ng/ml and prior negative peripheral zone (PZ) biopsy and to estimate the sensitivity of TZ biopsy.
  • Overall, 215 patients were subjected to either transurethral resection of the prostate (n=162) or open enucleation of the adenoma (n=53).
  • RESULTS: The extended biopsy revealed prostate cancers in 21.2% of cases (58/273).
  • Prostate volume (p=0.023), TZ volume (p=0.027) and PSA/TZ density (p=0.007) were predictive of TZ cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Incidence. Male. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / epidemiology. Sensitivity and Specificity


55. Uffort EE, Jensen JC: Robotic-assisted laparoscopic simple prostatectomy: an alternative minimal invasive approach for prostate adenoma. J Robot Surg; 2010 May;4(1):7-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic simple prostatectomy: an alternative minimal invasive approach for prostate adenoma.
  • To substantiate robotic-assisted laparoscopic simple prostatectomy (RLSP) as an alternative minimal invasive approach for the treatment of prostatic adenoma.
  • Demographic and clinical data were collected on 15 men between May 2007 and October 2009 who underwent RLSP for urinary retention secondary to benign prostate hypertrophy (BPH) and complicated by significant median lobe hypertrophy, bladder diverticula and/or stones.
  • International Prostate Symptoms Score (IPSS), postvoid residual (PVR), prostate-specific antigen (PSA) and cystoscopy, urodynamics evaluation, and operative reports were reviewed and analyzed.
  • Eleven men (73%) had urinary retention at presentation, 93.3% had significant intravesical lobe hypertrophy, 13.3% had bladder diverticula with/without stones, and mean prostate volume was 70.85 ml.
  • Mean operative time, estimated blood loss, and adenoma weight were 128.8 min, 139.3 ml, and 46.4 g, respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):757-60 [15711263.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):14-21 [14685095.001]
  • [Cites] Urology. 2002 Oct;60(4):623-7 [12385922.001]
  • [Cites] J Endourol. 2009 Jan;23(1):129-33 [19119803.001]
  • [Cites] Urology. 2009 Apr;73(4):811-5 [19195694.001]
  • [Cites] J Urol. 2008 Feb;179(2):513-5 [18076926.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):41-5 [18090488.001]
  • [Cites] J Urol. 2001 Feb;165(2):459-62 [11176396.001]
  • [Cites] J Endourol. 2004 Feb;18(1):63-6; discussion 66-7 [15006057.001]
  • [Cites] Urology. 2002 Jul;60(1):39-45; discussion 45 [12100918.001]
  • [Cites] J Urol. 2006 May;175(5):1691-4 [16600732.001]
  • [Cites] J Urol. 2007 Apr;177(4):1419-22 [17382744.001]
  • (PMID = 27638565.001).
  • [ISSN] 1863-2483
  • [Journal-full-title] Journal of robotic surgery
  • [ISO-abbreviation] J Robot Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; BPH / Prostate adenoma / Prostate median lobe hypertrophy / Robotic prostatectomy / Robotic surgery / Simple prostatectomy
  •  go-up   go-down


56. Endo F, Shiga Y, Minagawa S, Iwabuchi T, Fujisaki A, Yashi M, Hattori K, Muraishi O: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence. Urology; 2010 Dec;76(6):1451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-eight consecutive patients with benign prostatic hyperplasia underwent HoLEP from January to December 2008.
  • The next 37 cases (Surgery 2) underwent anteroposterior dissection HoLEP, where adenoma was dissected antegradely.
  • Surgical quality indexes (hemoglobin change, operating time, resected prostate volume) between the 2 groups were compared.
  • All patients were assessed at 2 weeks postoperatively for clinical SUI, international prostate symptom score (IPSS), quality of life (QoL), and peak flow rates (Q(max)).
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Urinary Incontinence, Stress / prevention & control
  • [MeSH-minor] Aged. Dissection / methods. Humans. Learning Curve. Male. Middle Aged. Mucous Membrane / surgery. Organ Size. Prostate / pathology. Quality of Life. Retrospective Studies


57. Goodman M, Bostick RM, Dash C, Flanders WD, Mandel JS: Hypothesis: oxidative stress score as a combined measure of pro-oxidant and antioxidant exposures. Ann Epidemiol; 2007 May;17(5):394-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We illustrate this approach by using data from two previously-conducted case-control studies: a colonoscopy-based colorectal adenoma study, and a population-based prostate cancer study.
  • In this pilot illustration we found a substantial decrease in risk associated with a high OSS for both prostate cancer and colorectal adenoma.
  • [MeSH-major] Antioxidants / administration & dosage. Colorectal Neoplasms / epidemiology. Diet. Oxidative Stress / physiology. Prostatic Neoplasms / epidemiology. Reactive Oxygen Species / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Epidemiol. 2007 Nov;17(11):930; author reply 931 [17855113.001]
  • (PMID = 17462547.001).
  • [ISSN] 1047-2797
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species
  • [Number-of-references] 72
  •  go-up   go-down


58. Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL, Vasko V: GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res; 2009 Dec;15(4):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GABA receptor expression in benign and malignant thyroid tumors.
  • Neurotransmitter systems have recently been shown to be involved in multiple malignancies including breast, colon and prostate cancers.
  • We examined the expression patterns of the GABAergic system in 70 human thyroid tumor samples (13 follicular adenomas, 14 follicular carcinomas, 43 papillary carcinomas) and adjacent normal thyroid by immunohistochemistry.
  • Expression levels of GABAB R2 and GABA receptor associated protein (GABARAP) are increased in adenomas and thyroid cancer suggesting their role in early stages of thyroid tumorigenesis.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. Microtubule-Associated Proteins / metabolism. Receptors, GABA-A / metabolism. Receptors, GABA-B / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2006 Jul;144(3):332-44 [16527506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2803-8 [17296934.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):383-90 [11144533.001]
  • [Cites] Psychoneuroendocrinology. 1987;12(1):53-9 [2884685.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):69-80 [18221027.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):61-6 [7279009.001]
  • [Cites] Endocr Dev. 2007;10:140-72 [17684395.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Cell Tissue Res. 1981;220(4):873-9 [7296659.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2270-82 [11948410.001]
  • [Cites] Life Sci. 1990;46(21):1489-501 [2162457.001]
  • [Cites] Annu Rev Neurosci. 1994;17:569-602 [7516126.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51841-50 [14530254.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):27-30 [11121859.001]
  • [Cites] Prog Exp Tumor Res. 2007;39:91-8 [17314503.001]
  • [Cites] Med Hypotheses. 2006;67(1):33-5 [16516401.001]
  • [Cites] Thyroidology. 1989 Dec;1(3):105-8 [2484871.001]
  • [Cites] J Physiol Pharmacol. 1998 Jun;49(2):303-10 [9670113.001]
  • [Cites] Neuroscience. 1996 Aug;73(3):705-13 [8809792.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):414-24 [2380337.001]
  • [Cites] Med Sci Monit. 2001 May-Jun;7(3):377-81 [11386012.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Jun;18(2):247-53 [10464715.001]
  • [Cites] Neurosci Res. 1999 Nov;35(2):145-53 [10616918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18 [15325588.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3017-24 [16303767.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):97-116 [15027888.001]
  • (PMID = 19381877.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GABARAP protein, human; 0 / Microtubule-Associated Proteins; 0 / Receptors, GABA; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B
  •  go-up   go-down


59. Verschoyle RD, Greaves P, Patel K, Marsden DA, Brown K, Steward WP, Gescher AJ: Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer; 2008 Apr;44(6):898-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels.
  • We tested the hypotheses that silibinin or silipide, silibinin formulated with phospholipids, delays tumour development in TRAMP or Apc(Min) mice, genetic models of prostate or intestinal malignancies, respectively.
  • In Apc(Min) mice silibinin, but not silipide, had only a marginal adenoma number-reducing effect.
  • The results cautiously support the advancement of silipide to the stage of clinical investigation in prostate cancer.
  • [MeSH-major] Adenoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Intestinal Neoplasms / prevention & control. Phosphatidylcholines / therapeutic use. Prostatic Neoplasms / prevention & control. Silymarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343654.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C325/A6691; United Kingdom / Medical Research Council / / G0100874
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Phosphatidylcholines; 0 / Silymarin; 134499-06-2 / IdB 1016; 4RKY41TBTF / silybin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


60. Danilov VV, Vasil'chenko AV, Danilova TI, Besedin SA, Borshchenko SA, Danilov VV: [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma]. Urologiia; 2010 Nov-Dec;(6):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma].
  • After examination 47 patients with prostatic adenoma (mean age 63 years) received a course of alpha1-adenoblocker (omsulosin in a dose 0.4 mg/day).
  • Thus, long-term treatment with alpha1-adrenoblockers can be used as a pharmacourodynamic test to detect infravesical obstruction in patients with prostatic adenoma.
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Bladder Neck Obstruction / diagnosis. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427987.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


61. Apolikhin OI, Sivkov AV, Beshliev DA, Abdullin II: [Current opportunities of pharmacotherapy of prostatic adenoma]. Urologiia; 2010 Mar-Apr;(2):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current opportunities of pharmacotherapy of prostatic adenoma].
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-Antagonists / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


62. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ: Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol; 2010 Jan 21;8:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells.
  • We recently demonstrated that sensitivity to low folate availability is affected by the rate of polyamine biosynthesis, which is prominent in prostate cells.
  • We, therefore, hypothesized that prostate cells might be highly susceptible to genetic, epigenetic and phenotypic changes consequent to folate restriction.
  • RESULTS: We studied the consequences of long-term, mild folate depletion in a model comprised of three syngenic cell lines derived from the transgenic adenoma of the mouse prostate (TRAMP) model, recapitulating different stages of prostate cancer; benign, transformed and metastatic.
  • High-performance liquid chromatography analysis demonstrated that mild folate depletion (100 nM) sufficed to induce imbalance in both the nucleotide and AdoMet pools in all prostate cell lines.
  • These genomic changes coincided with phenotype changes in the prostate cells including increased anchorage-independent growth and reduced sensitivity to folate depletion.
  • CONCLUSIONS: This study demonstrates that prostate cells are highly susceptible to genetic and epigenetic changes consequent to mild folate depletion as compared to cells grown with supraphysiological amounts of folate (2 microM) routinely used in tissue culture.
  • These results provide a strong rationale for studying the effects of folate manipulation on the prostate in vivo, where cells might be more sensitive to changes in folate status resulting from folate supplementation or antifolate therapeutic approaches.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6872-80 [15286716.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Mutat Res. 2006 Jan 29;593(1-2):80-7 [16144704.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Genome Res. 2006 Oct;16(10):1222-30 [16954539.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10308-14 [17079450.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10349-56 [17079455.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):178-86 [17080009.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):216S-222S [17182829.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):373-90 [17464296.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):524-42 [17896913.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e119 [17855397.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] BMC Genomics. 2007;8:446 [18053125.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Nutr Biochem. 2008 May;19(5):328-35 [17681772.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 18;101(6):432-5 [19276452.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2888-97 [19417083.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Nutr Cancer. 2000;37(2):245-51 [11142099.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Am J Hum Genet. 1979 Mar;31(2):125-35 [36752.001]
  • [Cites] Clin Chem. 1988 Nov;34(11):2357-9 [3141087.001]
  • [Cites] Cell Prolif. 1993 Jul;26(4):327-36 [8343561.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1433-43 [7503794.001]
  • [Cites] DNA Cell Biol. 1996 Mar;15(3):255-62 [8634154.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):31-8 [9097976.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3909-16 [12032829.001]
  • [Cites] Methods. 2002 Jun;27(2):144-9 [12095273.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):69-75 [12359353.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):453-8 [12355068.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2071-6 [9395204.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):81-90 [12538352.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):375-80 [12653642.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3740S-3747S [14608108.001]
  • [Cites] Mutat Res. 2004 Apr 14;548(1-2):53-9 [15063136.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • (PMID = 20092614.001).
  • [ISSN] 1741-7007
  • [Journal-full-title] BMC biology
  • [ISO-abbreviation] BMC Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21 CA131646; United States / NCI NIH HHS / CA / CA016056; United States / NCI NIH HHS / CA / R21 CA121216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine
  • [Other-IDs] NLM/ PMC2845099
  •  go-up   go-down


63. Pushkar' DIu, Dul'kin LM, Pletner DL, Bormotin AV, Liaginskiĭ AB: [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma].
  • The aim of our study was assessment of efficacy of PLFT technique on ProstaLund CoreTHerm unit in nanagement of acute urine retention in patients with prostatic adenoma.
  • We treated 31 patients with prostatic adenoma (age 58-97, mean age 74 years, volume of the prostatic gland from 32 to 188 ml); 11 patients had suprapubic fistula, 8 carried urethral catheter for acute urinary retention.
  • PLFT destroyed 15 +/- 5% prostatic tissue in each of the treated patients.
  • Thus, PLFT is a highly effective and save treatment of prostatic adenoma and can be recommended as a standard management of patients with acute urinary retention at high surgical risk.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. Recovery of Function. Transurethral Resection of Prostate / methods. Urination

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169717.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


64. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF: A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol; 2009 May;7(5):568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Aberrant crypt foci (ACF) are the putative precursor of colorectal adenomas.
  • METHODS: Subjects from the Prostate, Lung, Colorectal and Ovarian cancer screening trial were recruited for an ACF study, with subjects with adenoma history being oversampled.
  • RESULTS: A total of 505 (66% male; 55% > or =70 y) subjects from 4 institutions were examined; 42% had no adenoma, 32% had nonadvanced distal adenoma, and 25% had advanced distal adenoma at the baseline Prostate, Lung, Colorectal and Ovarian cancer screening trial examination (8.2 years before ACF examination on average).
  • Baseline adenoma status was not associated with ACF prevalence (range, 66%-69%) or mean number of ACF (range, 3.1-3.5).
  • CONCLUSIONS: ACF prevalence and number were not associated with adenoma history, and only 68.5% of endoscopic ACF were confirmed histologically.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418605.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


65. Danilov VV, Elisseva EV, Vasil'chenko AV: [Tadenan treatment of prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):68, 70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tadenan treatment of prostatic adenoma].
  • Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526878.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Fatty Alcohols; 0 / Plant Extracts; 0 / Tadenan
  •  go-up   go-down


66. Desai MM, Fareed K, Berger AK, Astigueta JC, Irwin BH, Aron M, Ulchaker J, Sotelo R: Single-port transvesical enucleation of the prostate: a clinical report of 34 cases. BJU Int; 2010 May;105(9):1296-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-port transvesical enucleation of the prostate: a clinical report of 34 cases.
  • OBJECTIVE: To present our experience with single-port transvesical enucleation of the prostate (STEP) in 34 patients with large-volume benign prostatic hyperplasia (BPH).
  • The mean prostate volume estimated by transrectal ultrasonography was 102.5 mL and the mean baseline prostate-specific antigen level was 6.7 ng/mL.
  • After establishing pneumovesicum, the prostate adenoma was enucleated transvesically using standard laparoscopic instruments, and the adenoma was extracted in pieces through the port.
  • Digital assistance expedited enucleation of the apical adenoma in 19 (55%) cases.
  • Under pneumovesicum using laparoscopic visualization, the entire adenoma can be effectively enucleated and expeditiously extracted through the novel single port.
  • [MeSH-major] Laparoscopy. Laser Therapy / methods. Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346053.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Pandak N, Tomić-Paradzik M, Krizanović B, Fornet-Sapcevski J: [The importance of Streptococcus bovis systemic infections]. Lijec Vjesn; 2006 Jul-Aug;128(7-8):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These infections are frequently connected with malignant, potentially malignant, or benign colorectal neoplasia.
  • He was an older man, who had undergone prostatectomy due prostatic adenoma several years before.
  • Histologically, in both cases, those were benign neoplasia.
  • [MeSH-minor] Adult. Aged. Bacteremia / diagnosis. Bacteremia / therapy. Humans. Male. Meningitis, Bacterial / diagnosis. Meningitis, Bacterial / microbiology. Meningitis, Bacterial / therapy

  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087134.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


68. Bartoletti R, Cai T, Tinacci G, Longo I, Ricci A, Massaro MP, Tosoratti N, Zini E, Pinzi N: Transperineal microwave thermoablation in patients with obstructive benign prostatic hyperplasia: a phase I clinical study with a new mini-choked microwave applicator. J Endourol; 2008 Jul;22(7):1509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transperineal microwave thermoablation in patients with obstructive benign prostatic hyperplasia: a phase I clinical study with a new mini-choked microwave applicator.
  • PURPOSE: To evaluate the tolerability and safety of a newly designed probe for trans-perineal microwave thermoablation (TPMT) of the prostate in patients with benign prostatic hyperplasia (BPH), and the in vivo microwave effects on prostatic tissue.
  • Then the International Index of Erectile Function (IIEF-5) and International Prostate Symptom Score (IPSS) questionnaires were administered to each patient at baseline and 1 month after prostatectomy in order to evaluate sexual and urinary function, respectively.
  • The prostatic adenomas were then evaluated by a pathologist.
  • Quasi-spheroid lesions with a well-defined area of complete coagulative necrosis were documented in all removed adenomas 7, 15, and 30 days after TMPT.

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613779.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Mireku-Boateng AO, Jackson AG: Prostate fossa packing: a simple, quick and effective method of achieving hemostasis in suprapubic prostatectomy. Urol Int; 2005;74(2):180-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate fossa packing: a simple, quick and effective method of achieving hemostasis in suprapubic prostatectomy.
  • INTRODUCTION: Suprapubic prostatectomy remains a very common surgical treatment for bladder outlet obstruction from an enlarged prostate in the developing world.
  • We describe our experience with prostatic fossa packing at the time of the procedure, as a very simple, quick and effective technique for maximal hemostasis.
  • CONCLUSION: Packing of the prostatic fossa at the time of enucleation of the adenoma is a very simple, quick and effective way to achieve hemostasis in suprapubic prostatectomy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756072.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


70. Blah M, Gobet F, Dugardin F, Catovic B, Loisel F, Pfister C: [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?]. Prog Urol; 2008 Feb;18(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?].
  • [Transliterated title] Elévation du PSA total après instillations endovesicales de BCG: prostatite granulomateuse ou adénocarcinome prostatique?
  • OBJECTIVE: The objective of this study was to evaluate the incidence of prostatic carcinoma in patients treated by intravesical BCG-therapy for superficial bladder cancer and presenting granulomatous prostatitis.
  • The authors discuss the problems of interpretation of total PSA and the potential indications for prostatic biopsies in this population.
  • Ultrasound-guided biopsies were indicated in view of the persistently elevated PSA level and confirmed the tuberculoid granulomatous lesion of the prostate in each case and revealed prostatic adenocarcinoma in two patients.
  • CONCLUSION: Prostatic carcinoma must be systematically excluded by ultrasound-guided biopsies in all patients with clinical granulomatous prostatitis and persistently elevated PSA three months after intravesical BCG instillations.
  • [MeSH-major] Adenoma / diagnosis. BCG Vaccine / administration & dosage. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Prostatitis / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Diagnosis, Differential. Drug Administration Schedule. Humans. Male. Retrospective Studies


71. Molinié V, Baumert H: [New markers in prostate biopsies]. Actas Urol Esp; 2007 Oct;31(9):1009-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New markers in prostate biopsies].
  • [Transliterated title] Nuevos marcadores en las biopsias de próstata.
  • The use of serum prostate-specific antigen screening to facilitate early detection of prostate cancer has resulted in a dramatic increase in the number of prostate needle core biopsies which pathologists must examine.
  • This has been accompanied by a strong increase in the number of biopsies with ambiguous lesions, and an unequivocal diagnosis of malignancy is difficult to render, especially in the case of limited foci or in small atypical acinar lesions.
  • When assessing small foci of atypical glands upon needle biopsy, the pathologist searches for differences between the benign glands and atypical glands in terms of usual morphological features and in such cases, immunohistochemical stains for basal cell markers such as 34betaE12 antibody or antibodies directed against cytokeratin 5 and 6 and more recently p63 may be a useful adjuvant to identify basal cells which are typically present in benign glands but absent in prostatic carcinoma.
  • However several benign mimickers of prostate carcinoma, including atrophy, atypical adenomatous hyperplasia, nephrogenic adenoma can stain negatively with these antibodies and thus a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Alpha-methyl-coenzyme-A-racemase (AMACR) a new sensitive marker of prostate carcinoma, can be useful in confirming ambiguous lesion suspected for malignancy.
  • The aim of this review is to describe the histological features of prostatic carcinoma in case of small focus, and discuss the application of these new prostatic markers in the light of the current literature to highlight the best practice guidelines.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Keratins / analysis. Male. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18257370.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Number-of-references] 53
  •  go-up   go-down


72. Sinnadurai M, Cherukuri RK, Moses RG, Nasser E: Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists. J Clin Neurosci; 2010 Sep;17(9):1201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
  • Gonadotrophin-releasing hormone agonists (GnRHAs) are used in many clinical conditions, particularly prostate cancer.
  • Two months before presentation, he had a subcutaneous GnRHA (Goserelin) implant for treatment of locally advanced prostate cancer (Gleeson 4+3).
  • His vision improved post-operatively and his FSH, LH, testosterone, prostate specific antigen (PSA) levels returned to normal levels.
  • Histopathologic studies revealed a pituitary adenoma, which stained positive for FSH and LH.
  • The prostate cancer management was changed to an anti-androgen agent and a GnRH antagonist.
  • This case demonstrates that pituitary apoplexy can develop up to eight weeks after the initiation of treatment for prostate cancer with GnRHAs.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Goserelin / adverse effects. Pituitary Apoplexy / chemically induced. Pituitary Apoplexy / diagnosis. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2010. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20605467.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Drug Implants; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


73. Müller RM, Thalmann GN, Studer UE: [Old and new interventional therapies in the treatment of symptomatic benign prostate hyperplasia (BPH)]. Ther Umsch; 2006 Feb;63(2):129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Old and new interventional therapies in the treatment of symptomatic benign prostate hyperplasia (BPH)].
  • Benign Prostatic Hyperplasia is a common entity among the aging male population.
  • The androgen-estrogen ratio changes in favor of the estrogens, which leads to a growth of prostatic tissue, presenting histologically as hyperplasia.
  • LUTS has a structural and a functional component, the structural being caused by the size of the adenoma itself the functional depending on the muscle tone of the bladder neck and the prostatic urethra.
  • Electro-resection of the prostate (TUR-P) remains the standard therapy and the benchmark any new technology has to compete with.
  • The most promising of the newer techniques is the Holmium-Laser-Enucleation of the prostate (Laser-TUR-P), showing at least identical short- and median-term results, but a lower perioperative morbidity than TUR-P For several minimally-invasive techniques, indications are limited.
  • TUMT TUNA, WIT and laser-coagulation all produce a coagulation necrosis of the prostatic tissue by thermic damage with secondary tissue shrinking.
  • [MeSH-major] Catheter Ablation / methods. Laser Therapy / methods. Minimally Invasive Surgical Procedures / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514965.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 18
  •  go-up   go-down


74. Gorilkovskiĭ LM, Zingerenko MB: [Efficacy and safety of tulosine in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):60, 62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of tulosine in patients with prostatic adenoma].
  • The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA).
  • Ultrasound investigation found no significant changes in the adenoma size.
  • Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Sulfonamides / adverse effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526876.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


75. Zeng Y, Yokohira M, Takeuchi H, Saoo K, Yamakawa K, Matsuda Y, Hosokawa K, Li JQ, Ikeda M, Imaida K: Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Lett; 2005 May 26;222(2):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
  • Modifying effects of arctiin on prostate carcinogenesis in probasin/SV 40 T antigen (Tag) transgenic (TG) rats were examined.
  • Histopathological evaluation of prostate revealed that all the rats in any group developed adenocarcinoma in dorsolateral lobe of prostate, except two rats in 0.1% arctiin treated and one rat in 0.002% arctiin treated groups without prostate adenocarcinoma development.
  • However, there were no definite treatment-related changes with statistical significance in all parameters for prostate carcinomas measured in this experiment.
  • These results indicated that arctiin might not exert significant modifying effect on prostate carcinogenesis in SV 40 Tag TG rats at least under the present experiment.
  • [MeSH-major] Adenoma / physiopathology. Furans / pharmacology. Glucosides / pharmacology. Prostatic Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863263.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Antigens, Polyomavirus Transforming; 0 / Drugs, Chinese Herbal; 0 / Furans; 0 / Glucosides; 0 / probasin; TM5RQ949K7 / arctiin
  •  go-up   go-down


76. Miften M, Gayou O, Reitz B, Fuhrer R, Leicher B, Parda DS: IMRT planning and delivery incorporating daily dose from mega-voltage cone-beam computed tomography imaging. Med Phys; 2007 Oct;34(10):3760-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One head and neck cancer patient and four prostate cancer patients were planned and treated using this technique.
  • Dosimetric results from the prostate IMRT plans optimized with or without CB showed similar target coverage and comparable sparing of bladder and rectum volumes.
  • [MeSH-major] Adenoma / radiotherapy. Cone-Beam Computed Tomography / methods. Pituitary Neoplasms / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiometry / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985621.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Martov AG, Ergakov DV: [The experience in dutasteride use before transurethral prostatic resection for large adenoma]. Urologiia; 2008 Jul-Aug;(4):46, 48-50, 52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The experience in dutasteride use before transurethral prostatic resection for large adenoma].
  • Dutasterid is a novel effective inhibitor of 5-alpha reductase of both types which can be used in patients with large (more than 80 cm3) prostatic adenoma to prevent intra- and postoperative hemorrhagic complications before transurethral resection of the prostate (TUR).
  • The trial included 70 males aged 67-82 years (mean age 74 years) with large size prostatic adenoma (more than 80 cm3) having indications for prostatic TUR.
  • Patients with coagulopathy, suspected prostatic cancer, previous treatment with 5-alpha reductase inhibitors were not included.
  • We recommend to begin dutasterid administration in a dose 0.5 mg for 1 month before TUR not only for patients with larger prostate (greater than 80 cm3) but with smaller prostates (30-80 cm3) for prevention of hemorrhagic complications and better conditions for surgery.
  • [MeSH-major] Azasteroids / administration & dosage. Enzyme Inhibitors / administration & dosage. Preoperative Care. Prostatic Hyperplasia / surgery. Urogenital Surgical Procedures

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; O0J6XJN02I / Dutasteride
  •  go-up   go-down


78. Tkachuk VN, Tkachuk IN: [Vitaprost forte efficacy in patients with prostatic adenoma]. Urologiia; 2008 Jul-Aug;(4):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte efficacy in patients with prostatic adenoma].
  • Efficacy and safety of a new bioregulatory peptide vitaprost forte was studied in 30 patients with prostatic adenoma.
  • It is shown that this drug relieves clinical symptoms of the disease, improves quality of life, uroflowmetric parameters, reduces the size of the prostatic gland.
  • Vitaprost forte is more effective in patients with prostatic adenoma combined with chronic prostatitis.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Aged. Chronic Disease. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate / pathology. Prostate / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058362.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


79. Verschoyle RD, Greaves P, Cai H, Edwards RE, Steward WP, Gescher AJ: Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. Br J Cancer; 2007 Jan 29;96(2):248-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.
  • We tested the hypothesis that rice bran interferes with development of tumours in TAg, TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) or Apc(Min) mice, genetic models of mammary, prostate and intestinal carcinogenesis, respectively.
  • Consumption of rice bran reduced numbers of intestinal adenomas in Apc(Min) mice by 51% (P<0.01), compared to mice on control diet.
  • At 10% in the diet, rice bran did not significantly retard Apc(Min) adenoma development.
  • [MeSH-major] Breast Neoplasms / prevention & control. Dietary Fiber / administration & dosage. Disease Models, Animal. Intestinal Neoplasms / prevention & control. Oryza. Prostatic Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 1993;20(1):41-9 [8415129.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1367-80 [11478486.001]
  • [Cites] Mol Nutr Food Res. 2005 Jun;49(6):571-84 [15864783.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Carcinogenesis. 1997 Oct;18(10):1863-5 [9363991.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1709-11 [15470192.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):875-80 [12792738.001]
  • [Cites] Nutr Cancer. 2004;49(2):170-3 [15489210.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1015-25 [8942431.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Cell. 1989 Jul 28;58(2):249-55 [2546678.001]
  • [Cites] EMBO J. 1992 Dec;11(13):5013-20 [1464323.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2109-15 [10545413.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6367-70 [12438216.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1809-15 [15547721.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40 [12050094.001]
  • [Cites] Prostate Cancer Prostatic Dis. 1999 Mar;2(2):70-75 [12496841.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):533-8 [16465408.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):817-22 [12066215.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10350-5 [11504910.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1167-73 [10837006.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1988 Sep;36(9):3609-13 [3240551.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):219-44 [4957125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):921-7 [10783313.001]
  • [Cites] Am J Clin Pathol. 1954 Sep;24(9):1016-24 [13197333.001]
  • [Cites] J Nutr. 1993 Nov;123(11):1939-51 [8229312.001]
  • (PMID = 17211473.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0100874
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359993
  •  go-up   go-down


80. Sergienko NF, Begaev AI, Shchekochikhin AV, Vasil'chenko MI: [Choice of the surgery method in adenoma of the prostate gland]. Voen Med Zh; 2006 Jul;327(7):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choice of the surgery method in adenoma of the prostate gland].
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Humans. Male. Transurethral Resection of Prostate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977877.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


81. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase P1 (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production.
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] DNA / blood. DNA / metabolism. DNA / urine. DNA Methylation. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


82. Stulp RP, Herkert JC, Karrenbeld A, Mol B, Vos YJ, Sijmons RH: Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum. Hered Cancer Clin Pract; 2008;6(1):15-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lynch syndrome (HNPCC) is a dominantly inherited disorder characterized by germline defects in DNA mismatch repair (MMR) genes and the development of a variety of cancers, predominantly colorectal and endometrial.
  • Recently, she had been diagnosed with an undifferentiated carcinoma of the thyroid and an adenoma of her coecum.
  • Although the risks for some tumour types, including breast cancer, soft tissue sarcoma and prostate cancer, are not significantly increased in Lynch syndrome, MMR deficiency in the presence of a corresponding germline defect has been demonstrated in incidental cases of a growing range of tumour types, which is reviewed in this paper.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4486-94 [15483016.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Fam Cancer. 2008;7(3):191-8 [18049911.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Apr;47(4):326-32 [18181177.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):62-72 [17851451.001]
  • [Cites] Hum Mutat. 2007 Nov;28(11):1084-90 [17557300.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):543-5 [17666659.001]
  • [Cites] Fam Cancer. 2007;6(1):141-5 [17051350.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):e83 [17601929.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2349-56 [17440981.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):130-4 [17259933.001]
  • [Cites] Gut. 2006 Dec;55(12):1781-8 [16636019.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):135-6 [9326924.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Apr;18(4):269-78 [9087566.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Cancer. 1996 May 1;77(9):1836-43 [8646682.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Fam Cancer. 2004;3(2):123-7 [15340263.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):981-9 [15143336.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):17-25 [15236168.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1262-9 [15098177.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):954-64 [15077197.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):576-85 [14762794.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Fam Cancer. 2001;1(2):101-5 [14574005.001]
  • [Cites] Histopathology. 2003 Sep;43(3):297-9 [12940783.001]
  • [Cites] Am J Med Genet A. 2003 Aug 30;121A(2):159-62 [12910497.001]
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):213-6 [12549480.001]
  • [Cites] J Med Genet. 2002 May;39(5):335-9 [12011152.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):26-37 [11709755.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4074-80 [11600610.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4541-4 [11389087.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):87-91 [10206076.001]
  • [Cites] J Med Genet. 2005 Jun;42(6):491-6 [15937084.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4689-93 [16000562.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):415-21 [16083698.001]
  • [Cites] Eur J Hum Genet. 2006 May;14(5):561-6 [16418736.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):358-61 [16507833.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):437-41 [10598809.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1719-23 [10763829.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):353-5 [11066081.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):195-9 [16372347.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):193-6 [16405554.001]
  • [Cites] Am J Med Genet A. 2005 Dec 1;139A(2):96-105; discussion 96 [16283678.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1322-6 [16311127.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1886-91 [16144131.001]
  • (PMID = 19706203.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2735069
  •  go-up   go-down


83. Chakravarti B, Dwivedi SK, Mithal A, Chattopadhyay N: Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine; 2009 Jun;35(3):271-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One situation is loss of CaR expression, resulting in loss of growth suppressing effects of elevated extracellular Ca(2+) by CaR, reported in parathyroid adenoma and in colon carcinoma.
  • CaR signaling and effects have been studied in several cancers including ovarian cancers, gastrinomas, and gliomas in addition to comparatively detailed studies in breast, prostate, and colon cancers.
  • Pharmacological agonists and antagonists of CaR hold therapeutic promise depending on whether activation of CaR is required such as in case of colon cancer or inactivating the receptor is required as in the case of breast- and prostate tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10330-4 [9294210.001]
  • [Cites] Am J Obstet Gynecol. 1998 Feb;178(2):305-13 [9500491.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):598-608 [14966569.001]
  • [Cites] N Engl J Med. 1985 Feb 21;312(8):474-83 [3881673.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7553-7 [10713061.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1293-4; author reply 1295 [15026815.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):779-84 [12548575.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1267-74 [11701443.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1724-6 [8467485.001]
  • [Cites] Endocrinology. 2003 Dec;144(12):5188-93 [12970167.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1319-23 [8958305.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):698-714 [8969974.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4455-64 [12970324.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Bone. 2004 Sep;35(3):664-72 [15336602.001]
  • [Cites] Breast. 2004 Dec;13 Suppl 1:S19-28 [15585379.001]
  • [Cites] Acta Neuropathol. 1986;70(1):17-21 [3727931.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Sep;35(9):631-8 [7566395.001]
  • [Cites] Metabolism. 1984 Jan;33(1):50-3 [6690886.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2057-66 [10595935.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Nat Med. 2002 Jan;8(1):35-40 [11786904.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Aug;50(4):685-93 [17117294.001]
  • [Cites] Curr Osteoporos Rep. 2007 Sep;5(3):120-7 [17925193.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):779-86 [12632068.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):217-28 [15200145.001]
  • [Cites] N Engl J Med. 1997 Nov 20;337(21):1506-10 [9366582.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):496-502 [10507776.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94 [11134144.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2092-102 [11697806.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1149-55 [10837003.001]
  • [Cites] Tidsskr Nor Laegeforen. 1992 Aug 10;112(18):2346-8 [1329263.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34871-9 [11390379.001]
  • [Cites] Cell Biochem Biophys. 2000;33(1):63-95 [11322513.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1389-94 [9769374.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):221-6 [12119356.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):439-45 [15950968.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N141-5 [12412791.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):169-80 [16025223.001]
  • [Cites] J Urol. 1996 Nov;156(5):1691-5 [8863572.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E435-42 [12388158.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1996 Jul;5(4):307-15 [8823527.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1114-20 [9422777.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):220-30 [16281261.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:120-7 [10668488.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Mar;56(3):243-54 [9056538.001]
  • [Cites] Hum Pathol. 1982 May;13(5):454-8 [6281168.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1111-9 [15067332.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s [17062703.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):615-8 [10543980.001]
  • [Cites] Prostate. 1997 May 15;31(3):168-74 [9167768.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):61-70 [12746564.001]
  • [Cites] J Physiol. 1998 Dec 1;513 ( Pt 2):411-24 [9806992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4857-60 [3387442.001]
  • [Cites] J Lab Clin Med. 1994 Apr;123(4):547-55 [8145003.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2144-54 [15735754.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):596-606 [11796515.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18 [15615499.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 [12679445.001]
  • [Cites] J Comp Neurol. 1986 May 15;247(3):275-96 [3522658.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7 [17804294.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13566-71 [15347804.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3812-8 [12097294.001]
  • [Cites] In Vitro Cell Dev Biol. 1989 Jul;25(7):643-9 [2753852.001]
  • [Cites] Glia. 1996 May;17(1):39-51 [8723841.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):769-79 [14993236.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1312-7 [8636323.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Feb;280(2):F291-302 [11208605.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 May;290(5):E761-70 [16603723.001]
  • [Cites] Ther Apher Dial. 2005 Aug;9 Suppl 1:S27-34 [16109139.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1588-93 [9837810.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5031-6 [11016624.001]
  • [Cites] Glia. 1999 Mar;26(1):64-72 [10088673.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Jan;34(1):1-10 [17220661.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):148-58 [14699496.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):18-23 [18307015.001]
  • [Cites] J Cell Biochem. 1991 Jul;46(3):250-4 [1774225.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36865-75 [15215241.001]
  • [Cites] Semin Oncol. 1991 Jun;18(3):177-85 [2042059.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):510-8 [7967506.001]
  • [Cites] Science. 1986 Oct 10;234(4773):161-6 [3018928.001]
  • [Cites] Hum Mutat. 2000 Oct;16(4):281-96 [11013439.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6258s-6263s [17062710.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Mol Genet Metab. 1999 Oct;68(2):328-31 [10527684.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606 [8636374.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):389-94 [7493018.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] N Engl J Med. 1986 Apr 24;314(17):1094-101 [2870434.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):177-83 [10209148.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Mar;56(3):572-81 [6822654.001]
  • [Cites] Endocrinology. 1991 Jun;128(6):2999-3004 [2036974.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Sep;279(3):C691-9 [10942719.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 13;299(4):532-8 [12459170.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] EMBO J. 2006 Jul 12;25(13):2978-88 [16763551.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9065-73 [16982748.001]
  • [Cites] Clin Calcium. 2008 Jan;18(1):32-6 [18175869.001]
  • [Cites] Cytometry. 1996 May 1;24(1):64-73 [8723904.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3982-7 [6162540.001]
  • [Cites] J Comput Assist Tomogr. 1992 Nov-Dec;16(6):856-9 [1385498.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2482-9 [15059902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] J Neurosci Res. 1997 Apr 15;48(2):122-7 [9130140.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E329-37 [12700162.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):403-11 [12656660.001]
  • [Cites] Growth Factors. 2005 Jun;23(2):117-23 [16019433.001]
  • [Cites] Prostate. 2001 May 15;47(3):212-21 [11351351.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:353-61 [11085928.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1455-62 [17557293.001]
  • [Cites] Am J Respir Cell Mol Biol. 1994 Dec;11(6):701-6 [7946399.001]
  • [Cites] Diabetes. 2000 Mar;49(3):409-17 [10868962.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12919-25 [7759551.001]
  • [Cites] J Bone Miner Res. 1999 Jun;14(6):878-82 [10352095.001]
  • [Cites] Endocrinology. 1986 Nov;119(5):2284-9 [3464413.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):21267-75 [9694886.001]
  • [Cites] Biochem J. 1986 Sep 15;238(3):905-12 [2432886.001]
  • [Cites] Acta Diabetol Lat. 1979 Jan-Mar;16(1):9-18 [377879.001]
  • [Cites] Cancer Treat Rev. 2003 Jun;29(3):189-98 [12787713.001]
  • [Cites] News Physiol Sci. 2002 Apr;17:62-7 [11909994.001]
  • [Cites] J Histochem Cytochem. 2000 May;48(5):595-602 [10769043.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Mar;52(3):339-48 [10718832.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):245-89 [11773614.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24571-8 [11964407.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1727-36 [15637291.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):409-16 [11809689.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3481-6 [9329389.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):718-29 [14991763.001]
  • [Cites] Eur J Endocrinol. 2000 May;142(5):500-5 [10802529.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1206-13 [15657090.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):245-51 [12507303.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:695-723 [15473857.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1035-43 [17914073.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):899-908 [12952940.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):40-4 [17188489.001]
  • [Cites] Brain Res. 1999 Dec 18;851(1-2):116-24 [10642834.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jul;45(1):105-13 [874057.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 23;320(2):455-60 [15219850.001]
  • [Cites] Bone. 2004 Aug;35(2):479-88 [15268900.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):48-54 [7942181.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] Breast Cancer. 1999 Oct 25;6(4):292-297 [11091732.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):511-5 [16564154.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G403-11 [17463182.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):703-7 [9467597.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10173-83 [10187801.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53 [15807924.001]
  • [Cites] Support Care Cancer. 2007 Nov;15(11):1243-9 [17393190.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2620-8 [9006895.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):1-11 [10912782.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2908-16 [10342884.001]
  • [Cites] Front Biosci. 2003 May 01;8:s377-90 [12700051.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 16;269(2):427-32 [10708570.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7839-49 [12420221.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1753-60 [10749150.001]
  • [Cites] J Bone Miner Res. 1989 Dec;4(6):839-44 [2610020.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):88-96 [9011580.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4357-64 [11108243.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] Neuroepidemiology. 1990;9(1):2-16 [2330068.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Natl Med Assoc. 2007 Jan;99(1):35-45 [17304967.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1211-7 [14645111.001]
  • [Cites] Nihon Rinsho. 1998 Jun;56(6):1419-24 [9648458.001]
  • [Cites] Br J Urol. 1996 Jan;77(1):102-6 [8653278.001]
  • [Cites] In Vitro. 1984 Aug;20(8):652-62 [6500605.001]
  • [Cites] Endocrinology. 1993 Apr;132(4):1658-64 [8462465.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):725-51 [11787845.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17(7):1164-70 [12096830.001]
  • [Cites] Biochem Biophys Res Commun. 1975 Nov 17;67(2):525-9 [812497.001]
  • [Cites] Subcell Biochem. 2007;45:405-27 [18193646.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7 [17591815.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):355-60 [15225800.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34880-7 [11390380.001]
  • [Cites] Hosp Pract (Off Ed). 1992 Nov 15;27(11):51-8 [1331139.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):229-37 [15200146.001]
  • [Cites] J Bone Miner Res. 2003 Dec;18(12):2200-5 [14672355.001]
  • (PMID = 19011996.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcium-Sensing
  • [Number-of-references] 203
  •  go-up   go-down


84. Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhøffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Tørring N, Dyrskjøt L, Andersen CL, Orntoft TF: Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics; 2008 Jul;7(7):1214-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis.
  • To identify tissue- and tumor-specific alternative splicing, we used the GeneChip Human Exon 1.0 ST Array to measure whole-genome exon expression in 102 normal and cancer tissue samples of different stages from colon, urinary bladder, and prostate.
  • We identified 2069 candidate alternative splicing events between normal tissue samples from colon, bladder, and prostate and selected 15 splicing events for RT-PCR validation, 10 of which were successfully validated by RT-PCR and sequencing.
  • Furthermore 23, 19, and 18 candidate tumor-specific splicing alterations in colon, bladder, and prostate, respectively, were selected for RT-PCR validation on an independent set of 81 normal and tumor tissue samples.
  • In conclusion, we identified and validated alternative splicing between normal tissue samples from colon, bladder, and prostate in addition to cancer-specific splicing events in colon, bladder, and prostate cancer that may have diagnostic and prognostic implications.
  • [MeSH-major] Adenoma / genetics. Alternative Splicing / genetics. Colonic Neoplasms / genetics. Exons. Prostatic Neoplasms / genetics. Urinary Bladder Neoplasms / genetics


85. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ: The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int; 2005 Nov;96(7):1045-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
  • OBJECTIVES: To compare the clinical profile (age, comorbidities, symptom severity, and incidence of acute urinary retention, AUR), the type and duration of medical treatment, and indications for surgery of patients undergoing surgery for benign prostatic hyperplasia (BPH) in 1992 and 2002 at one centre.
  • The preoperative clinical profile was determined by assessing age, main comorbidities, prostatic volume, maximum urinary flow rate and symptom severity.
  • Open surgery was indicated in 18.8% of patients in 1992 (mean adenoma weight 73.8 g, sd 37.12) and in 28.6% in 2002 (79.8 g, sd 35.41; P = 0.625).
  • Significantly more patients had open surgery, perhaps because the progressive increase in prostate volume was not affected by the medical therapy used predominantly during this decade.
  • [MeSH-major] Adenoma / surgery. Patient Selection. Prostatectomy / trends. Prostatic Hyperplasia / surgery
  • [MeSH-minor] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / therapeutic use. Age Factors. Aged. Chi-Square Distribution. Cross-Sectional Studies. Disease Progression. Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Humans. Male. Middle Aged. Phytotherapy / utilization. Prostate / surgery. Retrospective Studies

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225526.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


86. Vinarov AZ, Aliaev IuG, Apolikhin OI, Mazo EB, Darenkov SP, Demidko IuL, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression]. Urologiia; 2010 Nov-Dec;(6):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression].
  • PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls.
  • Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively.
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged. Organ Size. Prostate / drug effects. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Quality of Life. Risk. Treatment Outcome. Urinary Bladder / physiopathology. Urinary Bladder / ultrasonography. Urinary Retention / etiology. Urinary Retention / physiopathology. Urinary Retention / prevention & control. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21433319.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


87. Rehman J, Khan SA, Sukkarieh T, Chughtai B, Waltzer WC: Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques. J Endourol; 2005 May;19(4):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques.
  • PURPOSE: We describe extraperitoneal laparoscopic resection of large prostatic adenomas (<100 g) as an alternative to open simple prostatectomy by both the transcapsular or Millin and the transvesical approaches.
  • PATIENTS AND METHODS: We have performed more than 20 laparoscopic prostatectomies (adenomectomies) for benign prostatic hyperplasia (BPH) for glands >100 g.
  • Using an extraperitoneal approach, enucleation of the obstructing prostatic lobes was performed with the aid of a Harmonic Scalpel and laparoscopic claw forceps.
  • The adenoma removed was approximately 138 g in the first case and 102 g in the second case.


88. Komarov RN, Gordetsov AS, Komarov NV, Kanashkin OV, Svetozrskiĭ NL, Gamaiunov SV: [Urgent problems of prostatic cancer diagnosis in a small district clinic]. Urologiia; 2006 May-Jun;(3):28-9, 31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urgent problems of prostatic cancer diagnosis in a small district clinic].
  • Diagnostic methods in prostatic pathology used in a surgical department of a small town of Pavlovo (Nizhny Novgorod Region) are analysed.
  • Infrared spectroscopy was for the first time used in Pavlovo for diagnosis of cancer.
  • Examination of 57 patients aged 38-89 years has detected prostatic cancer in 16 (28 +/- 5.9%) patients, chronic prostatitis in 6 (10.5 +/- 4%) patients, prostatic adenoma in 34 (59.6 +/- 6.4%) patients, prostatic abscess--in 1 (1.9 +/- 1.7%) patient.
  • Infrared spectroscopy of the blood serum according to the proposed technique provides accurate (91.2 +/- 4.8%, p < 0.01) differential diagnosis of benign and malignant diseases of the prostate.
  • [MeSH-major] Hospitals, District. Prostatic Neoplasms / diagnosis. Spectrophotometry, Infrared / methods
  • [MeSH-minor] Abscess / diagnosis. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male. Middle Aged. Prostatic Diseases / diagnosis. Prostatitis / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889086.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


89. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


90. Bangaru ML, Woodliff J, Raff H, Kansra S: Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease. PLoS One; 2010;5(4):e9893
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Cell Proliferation / drug effects. Curcumin / pharmacology. Pituitary ACTH Hypersecretion / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Synapse. 2000 Mar 1;35(3):228-33 [10657030.001]
  • [Cites] Curr Opin Oncol. 2000 Nov;12(6):543-9 [11085453.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Feb;54(2):183-8 [11207632.001]
  • [Cites] J Clin Invest. 2001 Oct;108(8):1123-31 [11602619.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):143-50 [11756235.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8329-37 [11756417.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):183-200 [12111695.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1281-7 [12379847.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):54-9 [12729363.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1101-8 [15367704.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):646-9 [6125785.001]
  • [Cites] J Cell Physiol. 1992 May;151(2):326-36 [1572907.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):609-16 [8760302.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2952-60 [9399940.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):656-61 [9764849.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):119-27 [9918209.001]
  • [Cites] Biochem Pharmacol. 1999 Oct 1;58(7):1167-72 [10484074.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2183-9 [15256484.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1055-9 [15754738.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36 [15950373.001]
  • [Cites] Biochem Pharmacol. 2005 Sep 1;70(5):700-13 [16023083.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:206-17 [16387689.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2563-71 [17041101.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2976-86 [16873443.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1022-30 [17363495.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):616-25 [17289836.001]
  • [Cites] Cell. 2007 Sep 7;130(5):769-74 [17803898.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):4158-67 [18450960.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):115-22 [18957506.001]
  • [Cites] Neuroendocrinology. 2009;90(3):292-300 [19684383.001]
  • [Cites] Endocr Relat Cancer. 2009 Dec;16(4):1339-50 [19726538.001]
  • [ErratumIn] PLoS One. 2010;5(4). doi:10.1371/annotation/38a101d6-a1f2-4a74-ab63-bc5c61e5f62b
  • (PMID = 20405005.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 9002-60-2 / Adrenocorticotropic Hormone; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ PMC2854133
  •  go-up   go-down


91. Babyatsky M, Lin J, Yio X, Chen A, Zhang JY, Zheng Y, Twyman C, Bao X, Schwartz M, Thung S, Lawrence Werther J, Itzkowitz S: Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis; 2009;26(2):143-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trefoil factor-3 (TFF3) is expressed by normal intestinal epithelial cells and its expression is maintained throughout the colon adenoma-carcinoma sequence.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Endocrinol Metab. 2008 Mar;19(2):74-81 [18054496.001]
  • [Cites] Glycoconj J. 2001 Nov-Dec;18(11-12):871-82 [12820721.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12 (26):4143-8 [16830362.001]
  • [Cites] Regul Pept. 2005 Apr 15;127(1-3):87-94 [15680474.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4036-44 [8033134.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):489-97 [8566596.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):375-9 [1985035.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1092-9 [12006524.001]
  • [Cites] Genomics. 2003 Jul;82(1):78-85 [12809678.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] J Pathol. 1997 Sep;183(1):30-8 [9370944.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1125-31 [9737246.001]
  • [Cites] Cell Tissue Res. 2001 Jan;303(1):109-15 [11235998.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7405-12 [16437709.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):60-9 [10611154.001]
  • [Cites] FASEB J. 1996 Nov;10 (13):1518-23 [8940297.001]
  • [Cites] J Cell Biol. 1979 Feb;80(2):248-65 [88453.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):12-20 [8419234.001]
  • [Cites] Endocrinology. 2006 Dec;147(12 ):5752-9 [16973727.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):509-15 [10821500.001]
  • [Cites] Clin Exp Metastasis. 2005;22(2):157-65 [16086236.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Endocr J. 2009;56(1):9-16 [18506086.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):932-4 [9462243.001]
  • [Cites] J Clin Invest. 2002 Jan;109 (2):193-204 [11805131.001]
  • [Cites] Annu Rev Physiol. 1996;58:253-73 [8815795.001]
  • [Cites] Acta Otolaryngol. 2001 Oct;121(7):849-53 [11718251.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6472-8 [16166422.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Sep;4(9):721-32 [14506475.001]
  • [Cites] J Histochem Cytochem. 2007 May;55(5):505-13 [17242463.001]
  • [Cites] J Pathol. 2007 Jul;212(3):278-86 [17471475.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9353-61 [7721858.001]
  • [Cites] Genomics. 1997 Feb 15;40(1):200-2 [9070946.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1330-5 [10194185.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1171-85 [12368191.001]
  • [Cites] J Biol Chem. 1993 Mar 25;268(9):6694-702 [8454642.001]
  • [Cites] Life Sci. 2005 Apr 15;76(22):2581-92 [15769482.001]
  • [Cites] FEBS Lett. 1989 Jun 19;250(1):85-90 [2737304.001]
  • [Cites] J Pathol. 1997 Sep;183(1):4-7 [9370940.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4680-90 [10848594.001]
  • [Cites] FASEB J. 2001 Feb;15(2):351-61 [11156951.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):397-408 [11310832.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):376-83 [8040278.001]
  • [Cites] Lab Invest. 1996 Jul;75(1):25-32 [8683937.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):369-77 [15645121.001]
  • [Cites] J Pathol. 1997 Aug;182(4):404-13 [9306961.001]
  • [Cites] J Pathol. 2002 Aug;197(5):582-8 [12210076.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):655-9 [12168114.001]
  • (PMID = 18979216.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA109189
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / Peptides; 0 / TFF3 protein, human; 0 / TFF3 protein, rat; 0 / Trefoil Factor-3
  •  go-up   go-down


92. Kocarnik JD, Hutter CM, Slattery ML, Berndt SI, Hsu L, Duggan DJ, Muehling J, Caan BJ, Beresford SA, Rajkovic A, Sarto GE, Marshall JR, Hammad N, Wallace RB, Makar KW, Prentice RL, Potter JD, Hayes RB, Peters U: Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. Cancer Epidemiol Biomarkers Prev; 2010 Dec;19(12):3131-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis.
  • We included Caucasians with colorectal adenoma or colorectal cancer and controls from 4 studies (total 3,891 cases, 4,490 controls): the Women's Health Initiative (WHI); the Diet, Activity and Lifestyle Study (DALS); a Minnesota population-based case-control study (MinnCCS); and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO).
  • RESULTS: SNP rs719725 was statistically significantly associated with risk of colorectal cancer in WHI (OR per A allele 1.19; 95% CI, 1.01-1.40; P(trend) = 0.04), marginally associated with adenoma risk in PLCO (OR per A allele 1.11; 95% CI, 0.99-1.25; P(trend) = 0.07), and not associated in DALS and MinnCCS.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):616-21 [19155440.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Nat Rev Genet. 2009 Jun;10(6):353-8 [19434079.001]
  • [Cites] Hum Mol Genet. 2008 Sep 1;17(17):2665-72 [18535017.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):75-80 [8988044.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):779-84 [8896888.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21 [14575943.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):887-92 [18004301.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11128-32 [18056436.001]
  • [Cites] PLoS One. 2007;2(9):e841 [17786212.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):989-94 [17618283.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):882-4 [19561607.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • (PMID = 20978172.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA048998-12A2; United States / WHI NIH HHS / WH / N01 WH032112; United States / WHI NIH HHS / WH / N01 WH042122; United States / NCI NIH HHS / CA / R01 CA059045; United States / PHS HHS / / 32105-6; United States / WHI NIH HHS / WH / N01 WH32115; United States / WHI NIH HHS / WH / N01 WH042110; None / None / / N01 WH032102; United States / WHI NIH HHS / WH / N01WH22110; United States / WHI NIH HHS / WH / WH024152; United States / NIA NIH HHS / AG / R01 AG014358; United States / NIA NIH HHS / AG / R01 AG14358; United States / WHI NIH HHS / WH / N01 WH042114; United States / WHI NIH HHS / WH / N01 WH032105; United States / WHI NIH HHS / WH / N01 WH042107; United States / WHI NIH HHS / WH / N01 WH042126; United States / NCI NIH HHS / CA / P01 CA53996; United States / WHI NIH HHS / WH / N01 WH032109; United States / NCI NIH HHS / CA / P01 CA053996; United States / WHI NIH HHS / WH / N01 WH032102; None / None / / N01 WH044221; United States / WHI NIH HHS / WH / N01 WH042108-011; United States / NCI NIH HHS / CA / CA059045-05; United States / NIA NIH HHS / AG / AG014358-06; United States / PHS HHS / / 42107-26; United States / PHS HHS / / 32115; United States / WHI NIH HHS / WH / N01 WH022110; United States / WHI NIH HHS / WH / N01 WH042121; United States / WHI NIH HHS / WH / N01 WH032111; United States / WHI NIH HHS / WH / N01 WH032122; United States / NCI NIH HHS / CA / CA048998-12A2; United States / WHI NIH HHS / WH / N01 WH032118; United States / NCI NIH HHS / CA / R01 CA048998; United States / NCI NIH HHS / CA / K22 CA118421-01; United States / NCI NIH HHS / CA / R25 CA094880; United States / WHI NIH HHS / WH / N01 WH042130; United States / NIA NIH HHS / AG / R01 AG014358-06; United States / NCI NIH HHS / CA / U01 CA137088; United States / WHI NIH HHS / WH / N01 WH042115; United States / WHI NIH HHS / WH / N01 WH042131; United States / WHI NIH HHS / WH / N01 WH042119; None / None / / N01 WH032100; United States / NCI NIH HHS / CA / P01 CA053996-30; United States / WHI NIH HHS / WH / N01 WH042116; United States / PHS HHS / / 32100-2; United States / NCI NIH HHS / CA / CA118421-01; United States / PHS HHS / / 24152; United States / NCI NIH HHS / CA / R01 CA059045-05; United States / Intramural NIH HHS / / ; United States / WHI NIH HHS / WH / N01 WH042117; United States / NCI NIH HHS / CA / R01 CA48998; United States / PHS HHS / / 42129-32; United States / WHI NIH HHS / WH / N01 WH042109; United States / NIH HHS / OD / N01 WH42124; United States / NCI NIH HHS / CA / R25 CA094880-01; United States / WHI NIH HHS / WH / N01 WH032106; United States / PHS HHS / / 32118-32119; United States / WHI NIH HHS / WH / N01 WH042132; None / None / / N01 WH042113; United States / NCI NIH HHS / CA / CA053996-30; United States / WHI NIH HHS / WH / N01 WH032100; United States / PHS HHS / / 32108-9; United States / WHI NIH HHS / WH / N01 WH044221; United States / NCI NIH HHS / CA / K22 CA118421; United States / WHI NIH HHS / WH / N01 WH042112; United States / WHI NIH HHS / WH / N01 WH042125; United States / NCI NIH HHS / CA / R01 CA120582-01; United States / WHI NIH HHS / WH / N01 WH042111; United States / WHI NIH HHS / WH / N01 WH042113; United States / NCI NIH HHS / CA / CA120582-01; United States / PHS HHS / / 32122; United States / WHI NIH HHS / WH / N01 WH022110-024; United States / NCI NIH HHS / CA / R01 CA120582; United States / WHI NIH HHS / WH / N01 WH042120; United States / WHI NIH HHS / WH / N01 WH032108; United States / PHS HHS / / 44221; United States / PHS HHS / / 32111-13; United States / WHI NIH HHS / WH / N01 WH042123; United States / NCI NIH HHS / CA / CA094880-01; United States / WHI NIH HHS / WH / N01 WH032119; United States / WHI NIH HHS / WH / N01 WH042129; United States / WHI NIH HHS / WH / N01 WH032113; United States / WHI NIH HHS / WH / N01 WH024152
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS248201; NLM/ PMC3005543
  •  go-up   go-down


93. Sung W, Park BD, Lee S, Chang SG: Villous adenoma of the urinary bladder. Int J Urol; 2008 Jun;15(6):551-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma of the urinary bladder.
  • Villous adenomas arising in the urinary tract are an uncommon occurrence.
  • They have been identified in the urachus, urethra, prostate, and throughout the bladder.
  • Villous adenomas arising in the bladder are rare tumors that have been described as isolated cases and a few case series.
  • We report a new case of a large villous adenoma arising in the bladder that was treated by transurethral resection.
  • [MeSH-major] Adenoma, Villous / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489648.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


94. Kokko A, Laiho P, Lehtonen R, Korja S, Carvajal-Carmona LG, Järvinen H, Mecklin JP, Eng C, Schleutker J, Tomlinson IP, Vahteristo P, Aaltonen LA: EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. BMC Cancer; 2006;6:145
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inactivation of the gene has been shown to correlate with progression of colorectal tumorigenesis, and somatic mutations have been reported in both colorectal and prostate tumors.
  • METHODS: Here we have analyzed the EPHB2 gene for germline alterations in 101 individuals either with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and CRC.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Polymorphism, Genetic. Precancerous Conditions / genetics. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2193-200 [10829038.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):312-20 [16819509.001]
  • [Cites] Cell. 2000 Oct 13;103(2):311-20 [11057903.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4810-5 [11156239.001]
  • [Cites] Cancer Lett. 2001 Mar 10;164(1):97-104 [11166921.001]
  • [Cites] J Pathol. 2001 Mar;193(3):286-94 [11241406.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]
  • [Cites] Cell. 2002 Oct 18;111(2):251-63 [12408869.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5252-6 [14614006.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):979-83 [15300251.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):371-4 [9119409.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75 [15928710.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6450-8 [16166419.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10170-3 [16288001.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):454-64 [16272170.001]
  • [Cites] J Med Genet. 2006 Jun;43(6):507-11 [16155194.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1529-31 [10995809.001]
  • (PMID = 16740153.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphB2
  • [Other-IDs] NLM/ PMC1513590
  •  go-up   go-down


95. Lopatkin NA, Maksimov VA, Khodyreva LA, Davydova EN: [Optimisation of early diagnosis of prostatic diseases in megapolis setting]. Urologiia; 2009 Sep-Oct;(5):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optimisation of early diagnosis of prostatic diseases in megapolis setting].
  • One of the aims in the strategy of Moscow health service is perfection of early diagnosis of urological diseases.
  • The number of ultrasonographies and transrectal ultrasonic investigations of the prostate rose from 21650 (2002) to 128890 (2007), the number of polyfocal biopsies--from 2165 (2002) to 12219 (2007).
  • The rate of detection of prostatic diseases increased from 1146 cases per 100000 adult male population (1999) to 2097 (2007).
  • Chronic prostatitis was registered in 17.8%, prostatic adenoma in 29.6% examinees, new cases of prostatic cancer were detected in 0.86% examinees.
  • Standard prostatic cancer morbidity rose from 30.4 to 47.0 per 100000 male population.
  • Percentage of early detected prostatic cancer increased from 42.9% in 2000 to 62% in 2007, detection of prostatic cancer stage III-IV reduced from 27.3% in 2000 to 16.6% in 2007.
  • Thus, new prophylactic measures improved efficacy of outpatient urological service, raised rate of detection of chronic prostatitis, prostatic adenoma, prostatic cancer
  • [MeSH-major] Prostatic Diseases / diagnosis. Urban Population
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Moscow / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213912.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


96. Reich O: Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):436-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • (PMID = 18069121.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


97. Kassie F, Kalscheuer S, Matise I, Ma L, Melkamu T, Upadhyaya P, Hecht SS: Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis; 2010 Feb;31(2):239-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In previous studies, we reported that indole-3-carbinol (I3C) and myo-inositol (MI) inhibit lung adenoma induced by tobacco smoke carcinogens in A/J mice.
  • The higher dose of I3C decreased multiplicities of tumors on the surface of the lung (26%, P = 0.0005), carcinoma incidence (38%), multiplicity (67%, P < 0.0001) and size (complete abolition of carcinoma with an area of >1.0 cm(2)) as well as adenoma with cellular pleomorphism (46%, P < 0.0001).
  • MI decreased multiplicities of pulmonary surface tumors (20%, P = 0.0005), adenoma with cellular pleomorphism (40%, P < 0.0001) and lung adenoma (52%, P < 0.0001) and the proportion of the biggest carcinoma (carcinoma with an area of >1.0 cm(2), P < 0.05).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5592-600 [19531648.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):757-72 [11195469.001]
  • [Cites] Cancer Lett. 2001 Jun 10;167(1):1-6 [11323092.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2927-36 [11420705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):642-6 [11830512.001]
  • [Cites] Carcinogenesis. 2002 Sep;23(9):1455-61 [12189187.001]
  • [Cites] Chest. 2003 Nov;124(5):1828-33 [14605056.001]
  • [Cites] Carcinogenesis. 2004 Feb;25(2):197-201 [14578161.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):45-52 [15179623.001]
  • [Cites] Nutr Cancer. 2004;48(1):84-94 [15203382.001]
  • [Cites] Prostate. 2004 Oct 1;61(2):153-60 [15305338.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2613-7 [2328487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9543-7 [1658785.001]
  • [Cites] Carcinogenesis. 1993 Sep;14(9):1975-7 [8403228.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5132-5 [8912846.001]
  • [Cites] Anticancer Res. 1996 Sep-Oct;16(5A):2709-12 [8917375.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):139-45 [9934861.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2053-9 [15240509.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:236-43 [15574364.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1137-41 [15797040.001]
  • [Cites] Blood. 2005 Jul 15;106(2):641-9 [15811958.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8548-57 [16166336.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):541-50 [16199440.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):717-28 [16332727.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4952-60 [16651453.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31 [16896044.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2116-23 [16704990.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2747-56 [17121921.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11494-501 [17145898.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2757-65 [17913854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7139-45 [18056164.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2458-64 [18413838.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Sep;1(4):285-97 [19138972.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):568-76 [19139007.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):519-32 [19318631.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):370-6 [19336734.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5764-71 [11126363.001]
  • (PMID = 19625346.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-102502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Indoles; 12001-76-2 / Vitamin B Complex; 3IN71E75Z5 / Urethane; 4L6452S749 / Inositol; 7Y2431GOM5 / vinyl carbamate; C11E72455F / indole-3-carbinol; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2812566
  •  go-up   go-down


98. Kumanov P, Nandipati KC, Tomova A, Robeva R, Agarwal A: Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod Biomed Online; 2005 Jun;10(6):786-812
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunoreactivity against the inhibin alpha-subunit was identified in all cases of adrenal cortical adenoma and carcinoma, and levels are suppressed in the malignant prostate disease.

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970011.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Follistatin; 0 / alpha-Macroglobulins; 104625-48-1 / Activins; 57285-09-3 / Inhibins
  • [Number-of-references] 114
  •  go-up   go-down


99. Pinsky PF, Schoen RE, Weissfeld JL, Kramer B, Hayes RB, Yokochi L, PLCO Project Team: Variability in flexible sigmoidoscopy performance among examiners in a screening trial. Clin Gastroenterol Hepatol; 2005 Aug;3(8):792-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the performance of examiners in the US randomized trial: the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • CVs were 29% for distal polyp detection and 21% for distal adenoma detection.
  • CONCLUSIONS: Considerable variability exists in the rates of positive screens and in polyp and adenoma detection rates among FSG examiners performing the procedures using a common protocol.
  • [MeSH-minor] Adenoma / diagnosis. Aged. Colonic Polyps / diagnosis. False Positive Reactions. Female. Gastroenterology. Humans. Male. Middle Aged. Nurse Practitioners. Randomized Controlled Trials as Topic. Sex Factors. Smoking / adverse effects. United States

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234008.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


100. Tarasov NI, Izmaĭlov RI: [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride]. Urologiia; 2009 Sep-Oct;(5):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
  • Combined treatment with doxasozine and finasteride was performed for 7.26 months in 38 patients with large-size prostatic adenoma (89.54 +/- 11.64 cm3).
  • The control group (28 patients with large prostatic adenoma) received surgical treatment alone.
  • Thus, combined treatment with doxasozine and finasteride can be the first-line treatment in patients with large prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatectomy. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209869.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down






Advertisement